WO2024033385A1 - Methods for hematopoietic stem and progenitor cell expansion and differentiation in three-dimensional silk scaffolds and uses thereof - Google Patents
Methods for hematopoietic stem and progenitor cell expansion and differentiation in three-dimensional silk scaffolds and uses thereof Download PDFInfo
- Publication number
- WO2024033385A1 WO2024033385A1 PCT/EP2023/071983 EP2023071983W WO2024033385A1 WO 2024033385 A1 WO2024033385 A1 WO 2024033385A1 EP 2023071983 W EP2023071983 W EP 2023071983W WO 2024033385 A1 WO2024033385 A1 WO 2024033385A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cells
- scaffold
- silk
- silk fibroin
- stem cells
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims abstract description 53
- 210000000130 stem cell Anatomy 0.000 title claims abstract description 39
- 210000003958 hematopoietic stem cell Anatomy 0.000 title claims abstract description 21
- 230000024245 cell differentiation Effects 0.000 title description 5
- 230000010261 cell growth Effects 0.000 title description 3
- 108010022355 Fibroins Proteins 0.000 claims abstract description 94
- 210000000601 blood cell Anatomy 0.000 claims abstract description 29
- 238000004519 manufacturing process Methods 0.000 claims abstract description 22
- 230000008093 supporting effect Effects 0.000 claims abstract description 10
- 210000004027 cell Anatomy 0.000 claims description 97
- 239000000017 hydrogel Substances 0.000 claims description 56
- 239000010410 layer Substances 0.000 claims description 53
- 101001105486 Homo sapiens Proteasome subunit alpha type-7 Proteins 0.000 claims description 44
- 102100021201 Proteasome subunit alpha type-7 Human genes 0.000 claims description 44
- 210000001772 blood platelet Anatomy 0.000 claims description 44
- 239000007787 solid Substances 0.000 claims description 44
- 210000003593 megakaryocyte Anatomy 0.000 claims description 35
- 210000003743 erythrocyte Anatomy 0.000 claims description 33
- 230000004069 differentiation Effects 0.000 claims description 32
- 210000002901 mesenchymal stem cell Anatomy 0.000 claims description 31
- 210000001185 bone marrow Anatomy 0.000 claims description 30
- 150000003839 salts Chemical class 0.000 claims description 27
- 230000003394 haemopoietic effect Effects 0.000 claims description 23
- 238000002386 leaching Methods 0.000 claims description 23
- 210000002540 macrophage Anatomy 0.000 claims description 17
- 210000004263 induced pluripotent stem cell Anatomy 0.000 claims description 16
- -1 laminins Proteins 0.000 claims description 16
- 210000000265 leukocyte Anatomy 0.000 claims description 16
- 210000002889 endothelial cell Anatomy 0.000 claims description 15
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 13
- 210000001671 embryonic stem cell Anatomy 0.000 claims description 13
- 210000000963 osteoblast Anatomy 0.000 claims description 13
- 239000008103 glucose Substances 0.000 claims description 12
- 239000003102 growth factor Substances 0.000 claims description 12
- 238000003501 co-culture Methods 0.000 claims description 11
- 210000003714 granulocyte Anatomy 0.000 claims description 11
- 210000004698 lymphocyte Anatomy 0.000 claims description 11
- 210000001789 adipocyte Anatomy 0.000 claims description 10
- 238000009826 distribution Methods 0.000 claims description 10
- 239000003814 drug Substances 0.000 claims description 10
- 230000011132 hemopoiesis Effects 0.000 claims description 10
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 9
- 210000003651 basophil Anatomy 0.000 claims description 9
- 210000003979 eosinophil Anatomy 0.000 claims description 9
- 210000002950 fibroblast Anatomy 0.000 claims description 9
- 210000001616 monocyte Anatomy 0.000 claims description 9
- 210000002569 neuron Anatomy 0.000 claims description 9
- 210000000440 neutrophil Anatomy 0.000 claims description 9
- 210000002997 osteoclast Anatomy 0.000 claims description 9
- 210000004409 osteocyte Anatomy 0.000 claims description 9
- 210000004786 perivascular cell Anatomy 0.000 claims description 9
- 102000004127 Cytokines Human genes 0.000 claims description 8
- 108090000695 Cytokines Proteins 0.000 claims description 8
- 238000012545 processing Methods 0.000 claims description 8
- 239000002356 single layer Substances 0.000 claims description 8
- 238000004113 cell culture Methods 0.000 claims description 7
- 229940079593 drug Drugs 0.000 claims description 7
- 230000003511 endothelial effect Effects 0.000 claims description 7
- 239000005556 hormone Substances 0.000 claims description 7
- 229940088597 hormone Drugs 0.000 claims description 7
- 210000001178 neural stem cell Anatomy 0.000 claims description 7
- 238000007639 printing Methods 0.000 claims description 7
- 230000003068 static effect Effects 0.000 claims description 7
- 102000016359 Fibronectins Human genes 0.000 claims description 6
- 108010067306 Fibronectins Proteins 0.000 claims description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 6
- 210000004369 blood Anatomy 0.000 claims description 6
- 239000008280 blood Substances 0.000 claims description 6
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 6
- 239000012530 fluid Substances 0.000 claims description 6
- 238000001727 in vivo Methods 0.000 claims description 6
- 229910052760 oxygen Inorganic materials 0.000 claims description 6
- 239000001301 oxygen Substances 0.000 claims description 6
- 210000002381 plasma Anatomy 0.000 claims description 6
- 239000011148 porous material Substances 0.000 claims description 6
- 108010088751 Albumins Proteins 0.000 claims description 5
- 102000009027 Albumins Human genes 0.000 claims description 5
- 102000004190 Enzymes Human genes 0.000 claims description 5
- 108090000790 Enzymes Proteins 0.000 claims description 5
- 102000003886 Glycoproteins Human genes 0.000 claims description 5
- 108090000288 Glycoproteins Proteins 0.000 claims description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims description 5
- 102000004877 Insulin Human genes 0.000 claims description 5
- 108090001061 Insulin Proteins 0.000 claims description 5
- 230000001413 cellular effect Effects 0.000 claims description 5
- 239000011247 coating layer Substances 0.000 claims description 5
- 238000006911 enzymatic reaction Methods 0.000 claims description 5
- 229940088598 enzyme Drugs 0.000 claims description 5
- 210000002744 extracellular matrix Anatomy 0.000 claims description 5
- 229940125396 insulin Drugs 0.000 claims description 5
- 102000004506 Blood Proteins Human genes 0.000 claims description 4
- 108010017384 Blood Proteins Proteins 0.000 claims description 4
- 102000008186 Collagen Human genes 0.000 claims description 4
- 108010035532 Collagen Proteins 0.000 claims description 4
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 claims description 4
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 claims description 4
- 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 claims description 4
- 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 claims description 4
- 239000000427 antigen Substances 0.000 claims description 4
- 108091007433 antigens Proteins 0.000 claims description 4
- 102000036639 antigens Human genes 0.000 claims description 4
- 230000000975 bioactive effect Effects 0.000 claims description 4
- 238000000576 coating method Methods 0.000 claims description 4
- 229920001436 collagen Polymers 0.000 claims description 4
- 238000007598 dipping method Methods 0.000 claims description 4
- 239000012634 fragment Substances 0.000 claims description 4
- 239000007943 implant Substances 0.000 claims description 4
- 239000000543 intermediate Substances 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 235000015097 nutrients Nutrition 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 239000000018 receptor agonist Substances 0.000 claims description 4
- 229940044601 receptor agonist Drugs 0.000 claims description 4
- 210000002966 serum Anatomy 0.000 claims description 4
- 108091033409 CRISPR Proteins 0.000 claims description 3
- 102000019034 Chemokines Human genes 0.000 claims description 3
- 108010012236 Chemokines Proteins 0.000 claims description 3
- 102000029816 Collagenase Human genes 0.000 claims description 3
- 108060005980 Collagenase Proteins 0.000 claims description 3
- 241000713666 Lentivirus Species 0.000 claims description 3
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
- 239000006143 cell culture medium Substances 0.000 claims description 3
- 235000012000 cholesterol Nutrition 0.000 claims description 3
- 239000011248 coating agent Substances 0.000 claims description 3
- 229960002424 collagenase Drugs 0.000 claims description 3
- 238000001523 electrospinning Methods 0.000 claims description 3
- 238000001891 gel spinning Methods 0.000 claims description 3
- 108020004707 nucleic acids Proteins 0.000 claims description 3
- 102000039446 nucleic acids Human genes 0.000 claims description 3
- 239000013612 plasmid Substances 0.000 claims description 3
- 108010004131 poly(beta-D-mannuronate) lyase Proteins 0.000 claims description 3
- 239000001509 sodium citrate Substances 0.000 claims description 3
- 238000005507 spraying Methods 0.000 claims description 3
- 239000000758 substrate Substances 0.000 claims description 3
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims description 2
- 102000009088 Angiopoietin-1 Human genes 0.000 claims description 2
- 108010048154 Angiopoietin-1 Proteins 0.000 claims description 2
- 238000010354 CRISPR gene editing Methods 0.000 claims description 2
- XUIIKFGFIJCVMT-GFCCVEGCSA-N D-thyroxine Chemical compound IC1=CC(C[C@@H](N)C(O)=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-GFCCVEGCSA-N 0.000 claims description 2
- 108020004414 DNA Proteins 0.000 claims description 2
- 102000016942 Elastin Human genes 0.000 claims description 2
- 108010014258 Elastin Proteins 0.000 claims description 2
- 108010067770 Endopeptidase K Proteins 0.000 claims description 2
- 101150021185 FGF gene Proteins 0.000 claims description 2
- 102000009123 Fibrin Human genes 0.000 claims description 2
- 108010073385 Fibrin Proteins 0.000 claims description 2
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 claims description 2
- 108010049003 Fibrinogen Proteins 0.000 claims description 2
- 102000008946 Fibrinogen Human genes 0.000 claims description 2
- 102000006395 Globulins Human genes 0.000 claims description 2
- 108010044091 Globulins Proteins 0.000 claims description 2
- 102000051325 Glucagon Human genes 0.000 claims description 2
- 108060003199 Glucagon Proteins 0.000 claims description 2
- 108010017080 Granulocyte Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102000004269 Granulocyte Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102000004457 Granulocyte-Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108060003951 Immunoglobulin Proteins 0.000 claims description 2
- 108090001117 Insulin-Like Growth Factor II Proteins 0.000 claims description 2
- 102000048143 Insulin-Like Growth Factor II Human genes 0.000 claims description 2
- 102000015696 Interleukins Human genes 0.000 claims description 2
- 108010063738 Interleukins Proteins 0.000 claims description 2
- 101000844802 Lacticaseibacillus rhamnosus Teichoic acid D-alanyltransferase Proteins 0.000 claims description 2
- 108010052014 Liberase Proteins 0.000 claims description 2
- 108090001030 Lipoproteins Proteins 0.000 claims description 2
- 102000004895 Lipoproteins Human genes 0.000 claims description 2
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 claims description 2
- 102000007651 Macrophage Colony-Stimulating Factor Human genes 0.000 claims description 2
- 108700011259 MicroRNAs Proteins 0.000 claims description 2
- 108010070047 Notch Receptors Proteins 0.000 claims description 2
- 102000016611 Proteoglycans Human genes 0.000 claims description 2
- 108010067787 Proteoglycans Proteins 0.000 claims description 2
- 108091030071 RNAI Proteins 0.000 claims description 2
- 108020004459 Small interfering RNA Proteins 0.000 claims description 2
- 108700012920 TNF Proteins 0.000 claims description 2
- 102000002938 Thrombospondin Human genes 0.000 claims description 2
- 108060008245 Thrombospondin Proteins 0.000 claims description 2
- AUYYCJSJGJYCDS-LBPRGKRZSA-N Thyrolar Chemical compound IC1=CC(C[C@H](N)C(O)=O)=CC(I)=C1OC1=CC=C(O)C(I)=C1 AUYYCJSJGJYCDS-LBPRGKRZSA-N 0.000 claims description 2
- 102000004338 Transferrin Human genes 0.000 claims description 2
- 108090000901 Transferrin Proteins 0.000 claims description 2
- 108050003627 Wnt Proteins 0.000 claims description 2
- 239000005557 antagonist Substances 0.000 claims description 2
- 239000002246 antineoplastic agent Substances 0.000 claims description 2
- 239000012228 culture supernatant Substances 0.000 claims description 2
- 229940127089 cytotoxic agent Drugs 0.000 claims description 2
- 239000006185 dispersion Substances 0.000 claims description 2
- 229920002549 elastin Polymers 0.000 claims description 2
- 229950003499 fibrin Drugs 0.000 claims description 2
- 229940012952 fibrinogen Drugs 0.000 claims description 2
- 230000009368 gene silencing by RNA Effects 0.000 claims description 2
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 claims description 2
- 229960004666 glucagon Drugs 0.000 claims description 2
- 229920002674 hyaluronan Polymers 0.000 claims description 2
- 229960003160 hyaluronic acid Drugs 0.000 claims description 2
- 229930195733 hydrocarbon Natural products 0.000 claims description 2
- 102000018358 immunoglobulin Human genes 0.000 claims description 2
- 229940072221 immunoglobulins Drugs 0.000 claims description 2
- 239000003112 inhibitor Substances 0.000 claims description 2
- 229940047122 interleukins Drugs 0.000 claims description 2
- 229940043355 kinase inhibitor Drugs 0.000 claims description 2
- 239000003446 ligand Substances 0.000 claims description 2
- 239000002679 microRNA Substances 0.000 claims description 2
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 2
- 229920005862 polyol Polymers 0.000 claims description 2
- 239000002464 receptor antagonist Substances 0.000 claims description 2
- 229940044551 receptor antagonist Drugs 0.000 claims description 2
- 239000003590 rho kinase inhibitor Substances 0.000 claims description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 2
- 239000003270 steroid hormone Substances 0.000 claims description 2
- 229940034208 thyroxine Drugs 0.000 claims description 2
- XUIIKFGFIJCVMT-UHFFFAOYSA-N thyroxine-binding globulin Natural products IC1=CC(CC([NH3+])C([O-])=O)=CC(I)=C1OC1=CC(I)=C(O)C(I)=C1 XUIIKFGFIJCVMT-UHFFFAOYSA-N 0.000 claims description 2
- 239000003053 toxin Substances 0.000 claims description 2
- 231100000765 toxin Toxicity 0.000 claims description 2
- 108700012359 toxins Proteins 0.000 claims description 2
- 239000012581 transferrin Substances 0.000 claims description 2
- 229940035722 triiodothyronine Drugs 0.000 claims description 2
- 239000000243 solution Substances 0.000 description 40
- 239000000203 mixture Substances 0.000 description 26
- 239000008273 gelatin Substances 0.000 description 24
- 229920000159 gelatin Polymers 0.000 description 24
- 108010010803 Gelatin Proteins 0.000 description 23
- 235000019322 gelatine Nutrition 0.000 description 23
- 235000011852 gelatine desserts Nutrition 0.000 description 23
- 239000002609 medium Substances 0.000 description 16
- 238000009472 formulation Methods 0.000 description 15
- 230000010412 perfusion Effects 0.000 description 13
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 235000010443 alginic acid Nutrition 0.000 description 9
- 229920000615 alginic acid Polymers 0.000 description 9
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 9
- 238000004624 confocal microscopy Methods 0.000 description 9
- 239000011780 sodium chloride Substances 0.000 description 9
- 239000007853 buffer solution Substances 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 230000007774 longterm Effects 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000007995 HEPES buffer Substances 0.000 description 7
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 7
- 239000000783 alginic acid Substances 0.000 description 7
- 229960001126 alginic acid Drugs 0.000 description 7
- 239000012620 biological material Substances 0.000 description 7
- 230000014509 gene expression Effects 0.000 description 7
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 6
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 6
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 6
- 229930182816 L-glutamine Natural products 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- 238000004458 analytical method Methods 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 239000000872 buffer Substances 0.000 description 6
- 238000001125 extrusion Methods 0.000 description 6
- 210000004700 fetal blood Anatomy 0.000 description 6
- 239000012091 fetal bovine serum Substances 0.000 description 6
- 238000004108 freeze drying Methods 0.000 description 6
- 230000001965 increasing effect Effects 0.000 description 6
- 210000005259 peripheral blood Anatomy 0.000 description 6
- 239000011886 peripheral blood Substances 0.000 description 6
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 6
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 6
- 241000255789 Bombyx mori Species 0.000 description 5
- 102100034195 Thrombopoietin Human genes 0.000 description 5
- 150000004781 alginic acids Chemical class 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 5
- 230000007159 enucleation Effects 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 230000003278 mimic effect Effects 0.000 description 5
- 230000000877 morphologic effect Effects 0.000 description 5
- 239000002105 nanoparticle Substances 0.000 description 5
- 239000002245 particle Substances 0.000 description 5
- 230000008569 process Effects 0.000 description 5
- 230000000717 retained effect Effects 0.000 description 5
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- RLFWWDJHLFCNIJ-UHFFFAOYSA-N 4-aminoantipyrine Chemical compound CN1C(C)=C(N)C(=O)N1C1=CC=CC=C1 RLFWWDJHLFCNIJ-UHFFFAOYSA-N 0.000 description 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 4
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 4
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 4
- 101000835093 Homo sapiens Transferrin receptor protein 1 Proteins 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 4
- 230000008021 deposition Effects 0.000 description 4
- 238000004090 dissolution Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 239000006481 glucose medium Substances 0.000 description 4
- 239000001963 growth medium Substances 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- 239000011159 matrix material Substances 0.000 description 4
- 238000000465 moulding Methods 0.000 description 4
- 238000010899 nucleation Methods 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 238000011084 recovery Methods 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 238000013334 tissue model Methods 0.000 description 4
- 101001015004 Homo sapiens Integrin beta-3 Proteins 0.000 description 3
- 102100032999 Integrin beta-3 Human genes 0.000 description 3
- 229930182555 Penicillin Natural products 0.000 description 3
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 3
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 3
- 230000006399 behavior Effects 0.000 description 3
- 210000002798 bone marrow cell Anatomy 0.000 description 3
- 238000012512 characterization method Methods 0.000 description 3
- 238000010293 colony formation assay Methods 0.000 description 3
- 230000001332 colony forming effect Effects 0.000 description 3
- 238000010226 confocal imaging Methods 0.000 description 3
- 238000012136 culture method Methods 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 150000002303 glucose derivatives Chemical class 0.000 description 3
- 230000034659 glycolysis Effects 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 238000011065 in-situ storage Methods 0.000 description 3
- 238000009630 liquid culture Methods 0.000 description 3
- 229920000609 methyl cellulose Polymers 0.000 description 3
- 239000001923 methylcellulose Substances 0.000 description 3
- 238000000386 microscopy Methods 0.000 description 3
- 239000013642 negative control Substances 0.000 description 3
- 229940049954 penicillin Drugs 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 102000004169 proteins and genes Human genes 0.000 description 3
- 239000012679 serum free medium Substances 0.000 description 3
- 229910052710 silicon Inorganic materials 0.000 description 3
- 229940054269 sodium pyruvate Drugs 0.000 description 3
- 229960005322 streptomycin Drugs 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- VDABVNMGKGUPEY-UHFFFAOYSA-N 6-carboxyfluorescein succinimidyl ester Chemical compound C=1C(O)=CC=C2C=1OC1=CC(O)=CC=C1C2(C1=C2)OC(=O)C1=CC=C2C(=O)ON1C(=O)CCC1=O VDABVNMGKGUPEY-UHFFFAOYSA-N 0.000 description 2
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 2
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- SRBFZHDQGSBBOR-IOVATXLUSA-N D-xylopyranose Chemical compound O[C@@H]1COC(O)[C@H](O)[C@H]1O SRBFZHDQGSBBOR-IOVATXLUSA-N 0.000 description 2
- 101100220044 Homo sapiens CD34 gene Proteins 0.000 description 2
- 101000934372 Homo sapiens Macrosialin Proteins 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 2
- 108010073450 Lactate 2-monooxygenase Proteins 0.000 description 2
- 102100025136 Macrosialin Human genes 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-M Methacrylate Chemical compound CC(=C)C([O-])=O CERQOIWHTDAKMF-UHFFFAOYSA-M 0.000 description 2
- 241001529936 Murinae Species 0.000 description 2
- SEQKRHFRPICQDD-UHFFFAOYSA-N N-tris(hydroxymethyl)methylglycine Chemical compound OCC(CO)(CO)[NH2+]CC([O-])=O SEQKRHFRPICQDD-UHFFFAOYSA-N 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 150000001342 alkaline earth metals Chemical class 0.000 description 2
- PYMYPHUHKUWMLA-UHFFFAOYSA-N arabinose Natural products OCC(O)C(O)C(O)C=O PYMYPHUHKUWMLA-UHFFFAOYSA-N 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- 235000010323 ascorbic acid Nutrition 0.000 description 2
- 239000011668 ascorbic acid Substances 0.000 description 2
- 239000011324 bead Substances 0.000 description 2
- SRBFZHDQGSBBOR-UHFFFAOYSA-N beta-D-Pyranose-Lyxose Natural products OC1COC(O)C(O)C1O SRBFZHDQGSBBOR-UHFFFAOYSA-N 0.000 description 2
- 229910052791 calcium Inorganic materials 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 210000003850 cellular structure Anatomy 0.000 description 2
- 239000008119 colloidal silica Substances 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 238000004132 cross linking Methods 0.000 description 2
- 229960003957 dexamethasone Drugs 0.000 description 2
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 2
- 150000002016 disaccharides Chemical class 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 230000002449 erythroblastic effect Effects 0.000 description 2
- 239000003797 essential amino acid Substances 0.000 description 2
- 235000020776 essential amino acid Nutrition 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000004153 glucose metabolism Effects 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 238000003306 harvesting Methods 0.000 description 2
- 201000005787 hematologic cancer Diseases 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- CGIGDMFJXJATDK-UHFFFAOYSA-N indomethacin Chemical compound CC1=C(CC(O)=O)C2=CC(OC)=CC=C2N1C(=O)C1=CC=C(Cl)C=C1 CGIGDMFJXJATDK-UHFFFAOYSA-N 0.000 description 2
- AMXOYNBUYSYVKV-UHFFFAOYSA-M lithium bromide Chemical compound [Li+].[Br-] AMXOYNBUYSYVKV-UHFFFAOYSA-M 0.000 description 2
- 239000012528 membrane Substances 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 238000013508 migration Methods 0.000 description 2
- 210000003924 normoblast Anatomy 0.000 description 2
- 230000002572 peristaltic effect Effects 0.000 description 2
- 238000007747 plating Methods 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000010703 silicon Substances 0.000 description 2
- NMWCVZCSJHJYFW-UHFFFAOYSA-M sodium;3,5-dichloro-2-hydroxybenzenesulfonate Chemical compound [Na+].OC1=C(Cl)C=C(Cl)C=C1S([O-])(=O)=O NMWCVZCSJHJYFW-UHFFFAOYSA-M 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 150000005846 sugar alcohols Chemical class 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 238000012876 topography Methods 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- VRYALKFFQXWPIH-PBXRRBTRSA-N (3r,4s,5r)-3,4,5,6-tetrahydroxyhexanal Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)CC=O VRYALKFFQXWPIH-PBXRRBTRSA-N 0.000 description 1
- CWUAAQVTCQLNTH-UHFFFAOYSA-N 1-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OS(=O)(=O)C(C)N1CCN(CCO)CC1 CWUAAQVTCQLNTH-UHFFFAOYSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- DKVDSNMJXDQNCD-UHFFFAOYSA-N 1h-pyrrolo[2,3-f]quinazoline Chemical class N1=CN=CC2=C(NC=C3)C3=CC=C21 DKVDSNMJXDQNCD-UHFFFAOYSA-N 0.000 description 1
- QZTKDVCDBIDYMD-UHFFFAOYSA-N 2,2'-[(2-amino-2-oxoethyl)imino]diacetic acid Chemical compound NC(=O)CN(CC(O)=O)CC(O)=O QZTKDVCDBIDYMD-UHFFFAOYSA-N 0.000 description 1
- IHPYMWDTONKSCO-UHFFFAOYSA-N 2,2'-piperazine-1,4-diylbisethanesulfonic acid Chemical compound OS(=O)(=O)CCN1CCN(CCS(O)(=O)=O)CC1 IHPYMWDTONKSCO-UHFFFAOYSA-N 0.000 description 1
- AJTVSSFTXWNIRG-UHFFFAOYSA-N 2-[bis(2-hydroxyethyl)amino]ethanesulfonic acid Chemical compound OCC[NH+](CCO)CCS([O-])(=O)=O AJTVSSFTXWNIRG-UHFFFAOYSA-N 0.000 description 1
- UXFQFBNBSPQBJW-UHFFFAOYSA-N 2-amino-2-methylpropane-1,3-diol Chemical compound OCC(N)(C)CO UXFQFBNBSPQBJW-UHFFFAOYSA-N 0.000 description 1
- ACERFIHBIWMFOR-UHFFFAOYSA-N 2-hydroxy-3-[(1-hydroxy-2-methylpropan-2-yl)azaniumyl]propane-1-sulfonate Chemical compound OCC(C)(C)NCC(O)CS(O)(=O)=O ACERFIHBIWMFOR-UHFFFAOYSA-N 0.000 description 1
- LVQFQZZGTZFUNF-UHFFFAOYSA-N 2-hydroxy-3-[4-(2-hydroxy-3-sulfonatopropyl)piperazine-1,4-diium-1-yl]propane-1-sulfonate Chemical compound OS(=O)(=O)CC(O)CN1CCN(CC(O)CS(O)(=O)=O)CC1 LVQFQZZGTZFUNF-UHFFFAOYSA-N 0.000 description 1
- APIXJSLKIYYUKG-UHFFFAOYSA-N 3 Isobutyl 1 methylxanthine Chemical compound O=C1N(C)C(=O)N(CC(C)C)C2=C1N=CN2 APIXJSLKIYYUKG-UHFFFAOYSA-N 0.000 description 1
- DVLFYONBTKHTER-UHFFFAOYSA-N 3-(N-morpholino)propanesulfonic acid Chemical compound OS(=O)(=O)CCCN1CCOCC1 DVLFYONBTKHTER-UHFFFAOYSA-N 0.000 description 1
- INEWUCPYEUEQTN-UHFFFAOYSA-N 3-(cyclohexylamino)-2-hydroxy-1-propanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CNC1CCCCC1 INEWUCPYEUEQTN-UHFFFAOYSA-N 0.000 description 1
- NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
- RZQXOGQSPBYUKH-UHFFFAOYSA-N 3-[[1,3-dihydroxy-2-(hydroxymethyl)propan-2-yl]azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCC(CO)(CO)NCC(O)CS(O)(=O)=O RZQXOGQSPBYUKH-UHFFFAOYSA-N 0.000 description 1
- XCBLFURAFHFFJF-UHFFFAOYSA-N 3-[bis(2-hydroxyethyl)azaniumyl]-2-hydroxypropane-1-sulfonate Chemical compound OCCN(CCO)CC(O)CS(O)(=O)=O XCBLFURAFHFFJF-UHFFFAOYSA-N 0.000 description 1
- FWBHETKCLVMNFS-UHFFFAOYSA-N 4',6-Diamino-2-phenylindol Chemical compound C1=CC(C(=N)N)=CC=C1C1=CC2=CC=C(C(N)=N)C=C2N1 FWBHETKCLVMNFS-UHFFFAOYSA-N 0.000 description 1
- XNPKNHHFCKSMRV-UHFFFAOYSA-N 4-(cyclohexylamino)butane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCNC1CCCCC1 XNPKNHHFCKSMRV-UHFFFAOYSA-N 0.000 description 1
- BGFHMYJZJZLMHW-UHFFFAOYSA-N 4-[2-[[2-(1-benzothiophen-3-yl)-9-propan-2-ylpurin-6-yl]amino]ethyl]phenol Chemical compound N1=C(C=2C3=CC=CC=C3SC=2)N=C2N(C(C)C)C=NC2=C1NCCC1=CC=C(O)C=C1 BGFHMYJZJZLMHW-UHFFFAOYSA-N 0.000 description 1
- LOJNFONOHINEFI-UHFFFAOYSA-N 4-[4-(2-hydroxyethyl)piperazin-1-yl]butane-1-sulfonic acid Chemical compound OCCN1CCN(CCCCS(O)(=O)=O)CC1 LOJNFONOHINEFI-UHFFFAOYSA-N 0.000 description 1
- VTOWJTPBPWTSMK-UHFFFAOYSA-N 4-morpholin-4-ylbutane-1-sulfonic acid Chemical compound OS(=O)(=O)CCCCN1CCOCC1 VTOWJTPBPWTSMK-UHFFFAOYSA-N 0.000 description 1
- 239000007991 ACES buffer Substances 0.000 description 1
- 239000007988 ADA buffer Substances 0.000 description 1
- 101150035093 AMPD gene Proteins 0.000 description 1
- 102000002260 Alkaline Phosphatase Human genes 0.000 description 1
- 108020004774 Alkaline Phosphatase Proteins 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108050008874 Annexin Proteins 0.000 description 1
- 102000000412 Annexin Human genes 0.000 description 1
- 241000239290 Araneae Species 0.000 description 1
- 241000193935 Araneus diadematus Species 0.000 description 1
- 108700016232 Arg(2)-Sar(4)- dermorphin (1-4) Proteins 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 241000238421 Arthropoda Species 0.000 description 1
- 239000007992 BES buffer Substances 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 239000008000 CHES buffer Substances 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 102000012422 Collagen Type I Human genes 0.000 description 1
- 108010022452 Collagen Type I Proteins 0.000 description 1
- GUBGYTABKSRVRQ-CUHNMECISA-N D-Cellobiose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-CUHNMECISA-N 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- WQZGKKKJIJFFOK-IVMDWMLBSA-N D-allopyranose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@H](O)[C@@H]1O WQZGKKKJIJFFOK-IVMDWMLBSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- SHZGCJCMOBCMKK-UHFFFAOYSA-N D-mannomethylose Natural products CC1OC(O)C(O)C(O)C1O SHZGCJCMOBCMKK-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 1
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 description 1
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical compound ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 description 1
- 229920001917 Ficoll Polymers 0.000 description 1
- OZLGRUXZXMRXGP-UHFFFAOYSA-N Fluo-3 Chemical compound CC1=CC=C(N(CC(O)=O)CC(O)=O)C(OCCOC=2C(=CC=C(C=2)C2=C3C=C(Cl)C(=O)C=C3OC3=CC(O)=C(Cl)C=C32)N(CC(O)=O)CC(O)=O)=C1 OZLGRUXZXMRXGP-UHFFFAOYSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 108091052347 Glucose transporter family Proteins 0.000 description 1
- 102000042092 Glucose transporter family Human genes 0.000 description 1
- OWXMKDGYPWMGEB-UHFFFAOYSA-N HEPPS Chemical compound OCCN1CCN(CCCS(O)(=O)=O)CC1 OWXMKDGYPWMGEB-UHFFFAOYSA-N 0.000 description 1
- GIZQLVPDAOBAFN-UHFFFAOYSA-N HEPPSO Chemical compound OCCN1CCN(CC(O)CS(O)(=O)=O)CC1 GIZQLVPDAOBAFN-UHFFFAOYSA-N 0.000 description 1
- 101001078143 Homo sapiens Integrin alpha-IIb Proteins 0.000 description 1
- 101001070790 Homo sapiens Platelet glycoprotein Ib alpha chain Proteins 0.000 description 1
- 101000622304 Homo sapiens Vascular cell adhesion protein 1 Proteins 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 208000026350 Inborn Genetic disease Diseases 0.000 description 1
- 102100025306 Integrin alpha-IIb Human genes 0.000 description 1
- 108010002386 Interleukin-3 Proteins 0.000 description 1
- WQZGKKKJIJFFOK-VSOAQEOCSA-N L-altropyranose Chemical compound OC[C@@H]1OC(O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-VSOAQEOCSA-N 0.000 description 1
- WQZGKKKJIJFFOK-ZZWDRFIYSA-N L-glucose Chemical compound OC[C@@H]1OC(O)[C@@H](O)[C@H](O)[C@H]1O WQZGKKKJIJFFOK-ZZWDRFIYSA-N 0.000 description 1
- 102000003855 L-lactate dehydrogenase Human genes 0.000 description 1
- 108700023483 L-lactate dehydrogenases Proteins 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 102000007547 Laminin Human genes 0.000 description 1
- 108010085895 Laminin Proteins 0.000 description 1
- 235000007688 Lycopersicon esculentum Nutrition 0.000 description 1
- 239000007987 MES buffer Substances 0.000 description 1
- 239000007993 MOPS buffer Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- FSVCELGFZIQNCK-UHFFFAOYSA-N N,N-bis(2-hydroxyethyl)glycine Chemical compound OCCN(CCO)CC(O)=O FSVCELGFZIQNCK-UHFFFAOYSA-N 0.000 description 1
- DBXNUXBLKRLWFA-UHFFFAOYSA-N N-(2-acetamido)-2-aminoethanesulfonic acid Chemical compound NC(=O)CNCCS(O)(=O)=O DBXNUXBLKRLWFA-UHFFFAOYSA-N 0.000 description 1
- MKWKNSIESPFAQN-UHFFFAOYSA-N N-cyclohexyl-2-aminoethanesulfonic acid Chemical compound OS(=O)(=O)CCNC1CCCCC1 MKWKNSIESPFAQN-UHFFFAOYSA-N 0.000 description 1
- JOCBASBOOFNAJA-UHFFFAOYSA-N N-tris(hydroxymethyl)methyl-2-aminoethanesulfonic acid Chemical compound OCC(CO)(CO)NCCS(O)(=O)=O JOCBASBOOFNAJA-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 241000238902 Nephila clavipes Species 0.000 description 1
- 239000007990 PIPES buffer Substances 0.000 description 1
- 102100034173 Platelet glycoprotein Ib alpha chain Human genes 0.000 description 1
- 229920002845 Poly(methacrylic acid) Polymers 0.000 description 1
- LCTONWCANYUPML-UHFFFAOYSA-M Pyruvate Chemical compound CC(=O)C([O-])=O LCTONWCANYUPML-UHFFFAOYSA-M 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 108010013296 Sericins Proteins 0.000 description 1
- 240000003768 Solanum lycopersicum Species 0.000 description 1
- UZMAPBJVXOGOFT-UHFFFAOYSA-N Syringetin Natural products COC1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UZMAPBJVXOGOFT-UHFFFAOYSA-N 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000007994 TES buffer Substances 0.000 description 1
- 102000036693 Thrombopoietin Human genes 0.000 description 1
- 108010041111 Thrombopoietin Proteins 0.000 description 1
- 229940127323 Thrombopoietin Receptor Agonists Drugs 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 239000007997 Tricine buffer Substances 0.000 description 1
- 208000034953 Twin anemia-polycythemia sequence Diseases 0.000 description 1
- 102100023543 Vascular cell adhesion protein 1 Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- QOMNQGZXFYNBNG-UHFFFAOYSA-N acetyloxymethyl 2-[2-[2-[5-[3-(acetyloxymethoxy)-2,7-difluoro-6-oxoxanthen-9-yl]-2-[bis[2-(acetyloxymethoxy)-2-oxoethyl]amino]phenoxy]ethoxy]-n-[2-(acetyloxymethoxy)-2-oxoethyl]-4-methylanilino]acetate Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC1=CC(C2=C3C=C(F)C(=O)C=C3OC3=CC(OCOC(C)=O)=C(F)C=C32)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O QOMNQGZXFYNBNG-UHFFFAOYSA-N 0.000 description 1
- 238000005903 acid hydrolysis reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- UDMBCSSLTHHNCD-KQYNXXCUSA-N adenosine 5'-monophosphate Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H]1O UDMBCSSLTHHNCD-KQYNXXCUSA-N 0.000 description 1
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 1
- 238000005904 alkaline hydrolysis reaction Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- PMMURAAUARKVCB-UHFFFAOYSA-N alpha-D-ara-dHexp Natural products OCC1OC(O)CC(O)C1O PMMURAAUARKVCB-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 description 1
- HXXFSFRBOHSIMQ-VFUOTHLCSA-N alpha-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- PYMYPHUHKUWMLA-WDCZJNDASA-N arabinose Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)C=O PYMYPHUHKUWMLA-WDCZJNDASA-N 0.000 description 1
- 238000004630 atomic force microscopy Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- DLRVVLDZNNYCBX-ZZFZYMBESA-N beta-melibiose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](O)O1 DLRVVLDZNNYCBX-ZZFZYMBESA-N 0.000 description 1
- 210000002960 bfu-e Anatomy 0.000 description 1
- 239000007998 bicine buffer Substances 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 238000010322 bone marrow transplantation Methods 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- DEGAKNSWVGKMLS-UHFFFAOYSA-N calcein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC(CN(CC(O)=O)CC(O)=O)=C(O)C=C1OC1=C2C=C(CN(CC(O)=O)CC(=O)O)C(O)=C1 DEGAKNSWVGKMLS-UHFFFAOYSA-N 0.000 description 1
- 235000010410 calcium alginate Nutrition 0.000 description 1
- 239000000648 calcium alginate Substances 0.000 description 1
- 229960002681 calcium alginate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 230000011712 cell development Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000012292 cell migration Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000019522 cellular metabolic process Effects 0.000 description 1
- 239000007806 chemical reaction intermediate Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 150000001805 chlorine compounds Chemical class 0.000 description 1
- 238000007398 colorimetric assay Methods 0.000 description 1
- 238000011960 computer-aided design Methods 0.000 description 1
- 230000021615 conjugation Effects 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 230000010485 coping Effects 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 210000004443 dendritic cell Anatomy 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000005137 deposition process Methods 0.000 description 1
- KCFYHBSOLOXZIF-UHFFFAOYSA-N dihydrochrysin Natural products COC1=C(O)C(OC)=CC(C2OC3=CC(O)=CC(O)=C3C(=O)C2)=C1 KCFYHBSOLOXZIF-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 210000002472 endoplasmic reticulum Anatomy 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000007824 enzymatic assay Methods 0.000 description 1
- 230000000925 erythroid effect Effects 0.000 description 1
- 230000010437 erythropoiesis Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 238000001249 flow field-flow fractionation Methods 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- VPSRLGDRGCKUTK-UHFFFAOYSA-N fura-2-acetoxymethyl ester Chemical compound CC(=O)OCOC(=O)CN(CC(=O)OCOC(C)=O)C1=CC=C(C)C=C1OCCOC(C(=C1)N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)=CC2=C1OC(C=1OC(=CN=1)C(=O)OCOC(C)=O)=C2 VPSRLGDRGCKUTK-UHFFFAOYSA-N 0.000 description 1
- 229930182830 galactose Natural products 0.000 description 1
- 238000012239 gene modification Methods 0.000 description 1
- 208000016361 genetic disease Diseases 0.000 description 1
- 230000005017 genetic modification Effects 0.000 description 1
- 235000013617 genetically modified food Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950010772 glucose-1-phosphate Drugs 0.000 description 1
- 229940045189 glucose-6-phosphate Drugs 0.000 description 1
- 229940097043 glucuronic acid Drugs 0.000 description 1
- 239000003292 glue Substances 0.000 description 1
- 229960005150 glycerol Drugs 0.000 description 1
- 230000006545 glycolytic metabolism Effects 0.000 description 1
- YMAWOPBAYDPSLA-UHFFFAOYSA-N glycylglycine Chemical compound [NH3+]CC(=O)NCC([O-])=O YMAWOPBAYDPSLA-UHFFFAOYSA-N 0.000 description 1
- 210000002288 golgi apparatus Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 208000014951 hematologic disease Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 108010045676 holotransferrin Proteins 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010820 immunofluorescence microscopy Methods 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 229960000905 indomethacin Drugs 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000036512 infertility Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- JEIPFZHSYJVQDO-UHFFFAOYSA-N iron(III) oxide Inorganic materials O=[Fe]O[Fe]=O JEIPFZHSYJVQDO-UHFFFAOYSA-N 0.000 description 1
- 229940001447 lactate Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000010859 live-cell imaging Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- HWYHZTIRURJOHG-UHFFFAOYSA-N luminol Chemical compound O=C1NNC(=O)C2=C1C(N)=CC=C2 HWYHZTIRURJOHG-UHFFFAOYSA-N 0.000 description 1
- 239000012931 lyophilized formulation Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000001055 magnesium Nutrition 0.000 description 1
- 229940091250 magnesium supplement Drugs 0.000 description 1
- 229940049920 malate Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003470 mitochondria Anatomy 0.000 description 1
- 238000007479 molecular analysis Methods 0.000 description 1
- 210000002894 multi-fate stem cell Anatomy 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 210000003643 myeloid progenitor cell Anatomy 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 210000000822 natural killer cell Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000006911 nucleation Effects 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 229960002378 oftasceine Drugs 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 210000002220 organoid Anatomy 0.000 description 1
- 230000001582 osteoblastic effect Effects 0.000 description 1
- 230000002188 osteogenic effect Effects 0.000 description 1
- 238000006213 oxygenation reaction Methods 0.000 description 1
- 238000011422 pharmacological therapy Methods 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- KCRZDTROFIOPBP-UHFFFAOYSA-N phosphono 2,3-dihydroxypropanoate Chemical compound OCC(O)C(=O)OP(O)(O)=O KCRZDTROFIOPBP-UHFFFAOYSA-N 0.000 description 1
- 210000001778 pluripotent stem cell Anatomy 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000010408 potassium alginate Nutrition 0.000 description 1
- 239000000737 potassium alginate Substances 0.000 description 1
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 1
- XNSAINXGIQZQOO-SRVKXCTJSA-N protirelin Chemical compound NC(=O)[C@@H]1CCCN1C(=O)[C@@H](NC(=O)[C@H]1NC(=O)CC1)CC1=CN=CN1 XNSAINXGIQZQOO-SRVKXCTJSA-N 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 229940076788 pyruvate Drugs 0.000 description 1
- 239000002096 quantum dot Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 238000007634 remodeling Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- RWXWZOWDWYQKBK-UHFFFAOYSA-M rhod-2 dye Chemical compound [Br-].C=12C=CC(=[N+](C)C)C=C2OC2=CC(N(C)C)=CC=C2C=1C(C=1)=CC=C(N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O)C=1OCCOC1=CC(C)=CC=C1N(CC(=O)OCOC(C)=O)CC(=O)OCOC(C)=O RWXWZOWDWYQKBK-UHFFFAOYSA-M 0.000 description 1
- 238000004626 scanning electron microscopy Methods 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 239000002210 silicon-based material Substances 0.000 description 1
- 238000002791 soaking Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- 238000007711 solidification Methods 0.000 description 1
- 230000008023 solidification Effects 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 230000002269 spontaneous effect Effects 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 150000007944 thiolates Chemical class 0.000 description 1
- 230000035921 thrombopoiesis Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 229910021642 ultra pure water Inorganic materials 0.000 description 1
- 239000012498 ultrapure water Substances 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1311—Osteocytes, osteoblasts, odontoblasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1352—Mesenchymal stem cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
- C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2513/00—3D culture
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/50—Proteins
- C12N2533/54—Collagen; Gelatin
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/70—Polysaccharides
- C12N2533/74—Alginate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2533/00—Supports or coatings for cell culture, characterised by material
- C12N2533/90—Substrates of biological origin, e.g. extracellular matrix, decellularised tissue
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2537/00—Supports and/or coatings for cell culture characterised by physical or chemical treatment
- C12N2537/10—Cross-linking
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0641—Erythrocytes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0644—Platelets; Megakaryocytes
Definitions
- the present invention relates to silk fibroin-based scaffolds suitable for supporting the 3D culture of human hematopoietic stem and progenitor cells and/or the production of blood cells ex-vivo, and methods for producing the same.
- Hematopoiesis occurs in the bone marrow. Hematopoietic stem and progenitor cell (HSPC) fate decisions are dependent on signals from specialized microenvironments in the bone marrow, termed niches, three-dimensional (3D) environments that comprise cellular, chemical, and physical elements.
- HSPC Hematopoietic stem and progenitor cell
- Reproducing the human bone marrow niche is instrumental to answer the growing demand for human blood cells production ex-vivo either for fundamental studies or for clinical applications in the fields of transfusion and regenerative medicine, and bone marrow transplantation: models that recapitulate the complexity of human bone marrow can foster mechanistic studies of normal and malignant hematopoiesis and the validation of novel pharmacological therapies.
- HSPCs transplantation is the leading clinical application of cell-based therapies. Successful transplantations require a considerable amount of high-quality HSPCs to reconstitute long-term hematopoiesis. However, present-day procedures for harvesting and manipulating these cells cannot guarantee optimal therapeutic yield nor the quality of transplantable HSPCs. HSPC processing in conditions that reproduce their native bone marrow environment may lead to improvements in HSPC function and engraftment outcomes. More than 100 million units of blood are reported to be collected worldwide every year. Nevertheless, in no country does the contribution of volunteers succeed in coping with the growing demand, making it necessary to create alternative methods to produce blood cells. Ex-vivo manufacturing of mature blood cell products (i.e., erythrocytes and platelets) is becoming an increasingly attractive approach for both basic research and clinical applications (e.g., transfusion medicine).
- mature blood cell products i.e., erythrocytes and platelets
- HSPCs In vitro, culture conditions miss the bone marrow’s physical environment, which drives either HSPC self-renewal or differentiation into mature blood cells in vivo. In most of the current in vitro culture systems, HSPCs lose sternness a few hours after starting the culture, while differentiated blood cells look immature. For example, erythrocytes appear macrocytic, and platelets appear larger with immature granules. Also, it is known that cultured erythrocyte progenitors fail the enucleation process, while megakaryocytes of any origin produce fewer platelets per single cell than they do in vivo [1].
- 3D bone marrow organoids have been developed, though these systems allow the development of a self-made bone marrow microenvironment useful for mechanistic studies with limited possibility of experimental control and hampered cell harvesting and usage for clinical application (Khan et al., 2022 [2]).
- 3D scaffolds made of different types of organic (e.g., PEG, PCL, PU) and inorganic (e.g., HAp) biomaterials have been proposed to reproduce the 3D architecture as well as mechanical properties, nanopatterning, and topography of the native bone marrow. Also, their biofunctionalization through surface coatings, absorption, and/or covalent conjugation of ECM-derived molecules or cell-interacting motifs (e.g., collagen, fibronectin, laminin) has been proposed. Though, they could only support targeted HSPCs functions and concise experiments that hindered the possibility of transferring a single technique/approach into wide applications [1].
- organic e.g., PEG, PCL, PU
- inorganic (e.g., HAp) biomaterials have been proposed to reproduce the 3D architecture as well as mechanical properties, nanopatterning, and topography of the native bone marrow.
- ECM-derived molecules or cell-interacting motifs e.g., collagen, fibronect
- This system demonstrated the fundamental qualities of silk fibroin for studying thrombopoiesis, such as non-thrombogenicity and the possibility to entrap different molecules while retaining their bioactivity.
- a limitation of this model was the use of custom-made chambers and silk tubes whose production could not be standardized or scaled up easily to guarantee clinical applications.
- the second generation of silk-bone marrow models developed by the inventors (Di Buduo et al., 2017 [6], Tozzi et al., 2018 [7]) consisted of a scaled-up version intended to house a larger number of in vztro-derived megakaryocytes producing platelets for functional studies.
- the flow chambers were made of research-grade silicon or biomaterial, holding a silk sponge, prepared with salt leaching methods [6] or by lyophilization [7], and functionalized with extracellular matrix components (fibronectin [6], collagen IV [7]). Perfusion of the chambers allowed the recovery of platelets when the silk sponges were cultured with cord blood-derived megakaryocytes.
- a miniaturized system (Di Buduo et al., 2021 [8]; international patent application WO2021/11383OA1 [9]) could produce measurable numbers of platelets by megakaryocytes differentiated in vitro by HSPC derived from adult peripheral blood.
- prior art methods could not support long-term HSCPs expansion and retrieval or differentiation into different blood cell lineages.
- prior art methods could not support simultaneous long-term co-culture of HSPCs with other non-hematopoietic cell types (e.g., mesenchymal stem cells, osteoblasts, osteoclasts, osteocytes, fibroblasts, endothelial cells, perivascular cells, adipocytes, neurons).
- non-hematopoietic cell types e.g., mesenchymal stem cells, osteoblasts, osteoclasts, osteocytes, fibroblasts, endothelial cells, perivascular cells, adipocytes, neurons.
- prior art methods could not support simultaneous long-term co-culture of HSPCs with mature blood cells (e.g., leukocytes, granulocytes, monocytes, lymphocytes, neutrophils, eosinophils, basophils, macrophages, erythrocytes, megakaryocytes, and platelets).
- mature blood cells e.g., leukocytes, granulocytes, monocytes, lymphocytes, neutrophils, eosinophils, basophils, macrophages, erythrocytes, megakaryocytes, and platelets.
- prior art methods could not allow control over oxygen distribution within the culture.
- the present invention provides 3D silk scaffolds and methods for: human HSPC culture and expansion while keeping sternness in 3D silk scaffold.
- the culture method allows cell recovery for performing functional studies (e.g., colony formation assays, in situ differentiation).
- the culture methods allow the spontaneous formation of erythroblastic islands that support final erythrocyte maturation and enucleation.
- the improved culture method allows the production of an increased number of platelets with improved functionality with respect to previous methods and 2D liquid culture.
- HSPCs multi-layer scaffolds for the co-culture of HSPCs with mesenchymal stem cells, osteoblasts, osteoclasts, osteocytes, fibroblasts, endothelial cells, perivascular cells, adipocytes, neurons, leukocytes, granulocytes, monocytes, lymphocytes, neutrophils, eosinophils, basophils, macrophages, erythrocytes, platelets, megakaryocytes alone or in combination, to support improved HSPC differentiation.
- the stiffness of the silk scaffold to guide cell function may be regulated. silk scaffold perfusion into programmable flow chambers with a culture medium at different flow rates and timing (e.g.; continuous, intermittent).
- the composition of the perfused medium can be varied to guide HSPC quiescence, expansion or differentiation.
- a multi-layer scaffold can be assembled comprising at least two interconnected silk scaffolds: i) an inner core made of a porous solid silk fibroin scaffold or of a silk fibroin hydrogel comprising stem cells of the hematopoietic lineage; ii) at least one silk fibroin scaffold surrounding the inner scaffold i) made of silk fibroin hydrogel or porous solid silk fibroin scaffold comprising differentiated or undifferentiated cells selected between hematopoietic stem cells, or hematopoietic progenitor cells, mature blood cells and/or other non- hematopoietic cell types (e.g., mesenchymal stem cells, osteoblasts, osteoclasts, osteocytes, fibroblasts, endothelial cells, perivascular cells, adipocytes, neurons).
- non- hematopoietic cell types e.g., mesenchymal stem cells, osteoblasts, osteoclasts, osteocytes, fibroblasts,
- Solid and hydrogel silk scaffolds could be assembled into 3D multi-layer tissues that mimic the structure and composition of the different bone marrow microenvironments.
- the minimum number of layers is two. As many layers as needed can be added based on the experimental needs.
- Silk fibroin can be of a natural origin, such as, for example, fibroin produced by arthropods such as silkworms (e.g., Bombyx mori, Anthereae pernyi) or spiders (e.g., Nephila clavipes, Araneus diadematus).
- the silk fibroin can be of a recombinant origin, such as for example the fibroin produced by engineered systems (e.g.; bacteria, yeast).
- fibroin can be reconstituted from a lyophilized formulation.
- Silk fibroin can be chemically modified. According to a preferred embodiment, silk fibroin is extracted from Bombyx mori silkworm cocoons.
- resulting silk-based scaffolds can be arranged into predetermined patterns (e.g., cylindrical, rectangular, spherical, hexagonal) for controlled localization of at least two different cell types within the multi-layer scaffold.
- predetermined patterns e.g., cylindrical, rectangular, spherical, hexagonal
- the inner scaffold comprises stem cells of the hematopoietic lineage.
- the undifferentiated cells of the silk fibroin scaffold ii) are stem and progenitor cells of the hematopoietic lineage, mesenchymal stem cells, endothelial progenitor cells, neural stem cells, induced pluripotent stem cells or embryonic stem cells, when the 3D silk fibroin multi-layer scaffold further comprises one or more additional silk layer.
- said stem cells of the hematopoietic lineage are HSPCs.
- said stem cells of hematopoietic lineage are derived from induced pluripotent stem cells.
- said stem cells of hematopoietic lineage are derived from embryonic-derived cells.
- the solid silk scaffold, the hydrogel scaffold, or at least one of the two layers of the multi-layers scaffold comprises a cell component selected in the range of 0.01-100xl0 3 cells/mm 3 .
- the silk scaffold volume is a minimum of 3 mm 3 .
- the other layer (or layers) ii) comprises differentiated cells belonging to the category selected among mammalian osteoblasts, osteoclasts, osteocytes, fibroblasts, endothelial cells, perivascular cells, adipocytes, neurons, leukocytes, granulocytes, monocytes, lymphocytes, neutrophils, eosinophils, basophils, macrophages, erythrocytes, platelets, megakaryocytes and/or undifferentiated cells belonging to the category selected among stem and progenitor cells of the hematopoietic lineage, mesenchymal stem cells, endothelial progenitor cells, neural stem cells, induced pluripotent stem cells or embryonic stem cells, in the range of 0.1- lOOxlO 3 cells/mm 3 .
- At least two different cell types can be cocultured in the same or different layer.
- the porous solid silk fibroin scaffold comprises interconnected pores having a diameter > 5 pm.
- the porosity ensures the exchange of soluble factors and the possibility of cell migration among different compartments.
- the scaffolds according to the present invention were tested by culturing different cell types, such as human blood cancer cell lines, human HSPCs, murine HSPCs, human induced pluripotent stem cells, human and murine bone marrow cells, human and mouse mature blood cells, thus showing a wide versatility of use.
- cell types such as human blood cancer cell lines, human HSPCs, murine HSPCs, human induced pluripotent stem cells, human and murine bone marrow cells, human and mouse mature blood cells, thus showing a wide versatility of use.
- the silk fibroin scaffolds and hydrogels can be enriched with a different combination of differentiated cells belonging to the category selected among mammalian osteoblasts, osteoclasts, osteocytes, fibroblasts, endothelial cells, perivascular cells, adipocytes, neurons, leukocytes, granulocytes, monocytes, lymphocytes, neutrophils, eosinophils, basophils, macrophages, erythrocytes, platelets, megakaryocytes and/or undifferentiated cells belonging to the category selected among stem cells of the hematopoietic lineage, mesenchymal stem cells, endothelial progenitor cells, neural stem cells, induced pluripotent stem cells or embryonic stem cells, (alone or in different combinations).
- differentiated cells belonging to the category selected among mammalian osteoblasts, osteoclasts, osteocytes, fibroblasts, endothelial cells, perivascular cells, adipocytes
- the elasticity and viscosity of silk fibroin can be adjusted depending on the methods used for the fibroin extraction.
- Oxygen distribution inside the scaffold can be controlled by varying silk fibroin composition and assembly at the surface of the scaffolds and/or hydrogels.
- the solid silk scaffold NaCh particles (approximately >300 pm in diameter) were sifted into a silk solution (2-20% w/v) in a ratio of 1 mL silk/2 g salt, within a molding system (e.g., petri dish, silicon chamber).
- the scaffolds were then placed at room temperature for 48 hours and then soaked in distilled water for 48 hours to leach out the salt particles.
- the scaffolds were sterilized in 70% ethanol and finally rinsed five times in phosphate-buffered saline (PBS) over 24 hours.
- PBS phosphate-buffered saline
- the silk solution (1-20% w/v) was cast within the molding system and incubated at -80°C for one day.
- the frozen solution was then lyophilized for 48-72 hours at -56/-80°C.
- the lyophilized scaffolds were subsequently autoclaved for 20 minutes to induce the P-sheet formation and stabilize the silk matrix.
- Both types of silk scaffolds were characterized by confocal microscopy and scanning electron microscopy.
- silk fibroin degumming time (10, 20, 30, 40, 50, or 60 minutes) and final concentration (1-20%), and on P-sheet inducing parameters (salt leaching or lyophilization)
- the bulk region of these solid scaffolds can be prepared with control over a variety of factors, including, but not limited to, pore sizes and morphologies, mechanical properties, degradation rates, and any combinations thereof.
- the hydrogel silk scaffold is composed of:
- the cell component can be part of the initial formulation.
- the temperature of the silk hydrogel formulation is 37°C when the cells are to be added.
- Silk hydrogels were produced at 37°C. After deposition, the silk hydrogel could be crosslinked with a CaCh solution for a minimum of 10 minutes.
- the crosslinking solution preferably contains 0.05-0.1 M CaCh dissolved in a buffer solution containing NaCl, KC1, MgCh, glucose, and HEPES.
- the saline buffer solution contains: 150 mM NaCl, 6 mM KC1, 1 mM MgCh, 10 mM HEPES.
- the gelatin and alginic acid or their derivatives are present in a reciprocal ratio of about 15: 1.
- the fibroin and gelatin or its derivatives are present in a reciprocal ratio equal to about 1:5 or about 1:2 or 1: 0.5.
- the silk fibroin is dissolved in a solution comprising one or more ion sources selected from the group consisting of alkaline or alkaline earth metal 10 chlorides, such as for example MgCh, CaCh, NaCl, KC1.
- alkaline or alkaline earth metal 10 chlorides such as for example MgCh, CaCh, NaCl, KC1.
- gelatin used in the silk fibroin hydrogel formulation according to the invention can be type A (acid hydrolysis) or type B (alkaline hydrolysis).
- gelatin is of type A.
- the gelatin derivatives are selected from the group consisting of gelatin conjugated with chitosan, gelatin-poly(DL-lactide), gelatin modified with PEG, gelatin thiolates, DNA-gelatin nanospheres, gelatin nanoparticles, gelatin-coated fluorescent maghemite nanoparticles, gelatin-coated fluorescent polymethacrylic acid nanoparticles (FPMAAG), supramolecular gelatin nanoparticles coated with quantum dots, gelatin nanoparticles coated with iron oxide, gelatin methacrylate, xanthan gum human gelatin, recombinant gelatin, gelatin marked with fluorescent molecules.
- FPMAAG gelatin-coated fluorescent polymethacrylic acid nanoparticles
- the alginic acid derivatives are salts with alkaline and alkaline earth metals selected from the group consisting of sodium alginate, calcium alginate, magnesium alginate, and potassium alginate.
- methacrylate alginate can be used to produce photopolymerizable hydrogels in the presence of soluble photoinitiators.
- the glucose analogues are selected from the group consisting of disaccharides, stereoisomers, isomers, epimers, alditols or acids of glucose, precursors or products deriving from the glucose metabolism.
- Glucose analogues within the context of the present invention refer to metabolites that can be transported within the cell, become part of the glycolysis cycle, and metabolized.
- glucose analogues can be selected from the group consisting of: D-glucose, L-glucose, lactose, sucrose, trehalose, cellobiose, melibiose, maltose (disaccharides), mannitol, galactose, mannose, fructose (epimers), allose, altrose (stereoisomers), gluconic acid, glucuronic acid (acids), arabinose, glycerol, pyruvate, glucose 1-phosphate, glucose 6- phosphate, lactate, malate, phosphoglycerate, succinate (precursors or derivatives of the glucose metabolism), sorbitol (alditol).
- the glucose can also be replaced by fluorescent analogues that allow the glucose transportation to be monitored (e.g. 2-(N-(7-nitrobenz-2-oxa-l,3-diazol-4-yl)amino)-2- deoxyglucose) or analogues that inhibit the glycolytic metabolism (e.g. 2- deoxy-d-glucose).
- fluorescent analogues that allow the glucose transportation to be monitored
- analogues that inhibit the glycolytic metabolism e.g. 2- deoxy-d-glucose
- the controlled density solution is a controlled density solution selected from the group consisting of Percoll® (colloidal silica particles of 15-30 nm in diameter (23% w/w in water) coated with polyvinylpyrrolidone), Ficoll® (sucrose and epichlorohydrin copolymer), colloidal silica, copolymers (e.g. sucrose and epichlorohydrin), hydrophilic polysaccharides (e.g. sucrose), high-molecular-weight synthetic polymers (e.g. Polysucrose®).
- the controlled density solution is preferably Percoll®.
- the buffer be an organic or mineral buffer selected from the group consisting of: MES, ADA, ACES, PIPES, MOPSO, Bis-6Tris Propane, BES, MOPS, TES, HEPES, DIPSO, MOBS, TAPSO, HEPPSO, POPSO, EPPS, Tricine, Gly-Gly, Bicine, HEPBS, TAPS, AMPD, TABS, AMPSO, CHES, CAPSO, AMP, CAPS and CABS.
- the buffer is preferably HEPES (4-2- hydroxyethyl-l-piperazinyl-ethanesulfonic acid) which has strong buffering power.
- the ideal buffer system is selected that allows the desired pH, the subsequent culture, and in any type of manipulation and/or analysis of the scaffolds in an uncontrolled CO2 atmosphere.
- the presence of the buffer is an advantage during the deposition process. In this way, it is possible to keep the cells viable as they are maintained at a physiological pH, even outside of the incubator.
- the silk hydrogel formulation according to the invention always maintains a physiological pH. Without a buffer, the formulation can lose its physiological pH and this results in a reduction in cell vitality /functionality.
- the formulation according to the invention has the following composition: silk fibroin 8% w/v gelatin 15% w/v alginic acid 1% w/v glucose 3.5% w/v
- Solid and hydrogel silk scaffolds could be assembled into 3D multilayertissues that mimic the structure and composition of the different bone marrow microenvironments.
- the minimum number of layers is two. As many layers as needed can be added based on the experimental needs.
- the central core is a porous solid silk scaffold obtained by salt leaching processing of 50/60-minute degummed silk (6-8%) or by lyophilizing 30/60-minute degummed silk (2-6%).
- the second layer of the tissue model is fabricated with salt leaching methods using 10/30- minute degummed silk fibroin.
- the first silk scaffold is covered by a silk hydrogel according to the composition mentioned above.
- the silk hydrogel solution is dispensed at 37 °C around the first solid silk scaffold, and then crosslinked at room temperature.
- silk fibroin hydrogel is dispensed by manual pipetting.
- the hydrogel can be bio-printed around the solid silk fibroin scaffold through an extrusion-based approach with a nozzle having a caliber ranging from 18G to 27G, extrusion pressure within the range of 5-200 kPa, and printing rate within the range of 5-1,000 mm/min.
- the multi-layer model comprise at least two interconnected silk scaffolds, wherein at least one scaffold partially surrounds the other, and at least one of the scaffolds comprises interconnected pores, wherein pores have a diameter >5 pm.
- the present invention further relates to the use of the scaffolds described above as an ex-vivo model for keeping sternness, supporting hematopoiesis or for the production of mature blood cells (including erythrocytes, macrophages, megakaryocytes, leukocytes, granulocytes, lymphocytes, and platelets) through the use of growth factors or mediums that maintain the sternness or promote cell differentiation.
- the cells retrieved from the scaffolds may be used for morphological, functional characterization (e.g., expression of lineagedifferentiation markers; differentiation assays), and clinical applications (e.g., transfusion, transplant).
- the invention relates to the use of the scaffold described above as a surgical implant for keeping sternness, supporting hematopoiesis or for the production of erythrocytes, macrophages, megakaryocytes, leukocytes, granulocytes, lymphocytes, platelets, and other blood cells in vivo.
- said implant further comprises one or more drugs, hormones, growth, or differentiation factors that can be released in situ.
- the silk fibroin scaffolds, and hydrogels of the invention can be functionalized with bioactive molecules (i.e., enzymes, substrates and intermediates of enzymatic reactions, extracellular matrices, drugs, cytokines, chemokines, growth factors, hormones, proteins, and glycoproteins, cell- derived interacting motifs, biologic fluids).
- bioactive molecules i.e., enzymes, substrates and intermediates of enzymatic reactions, extracellular matrices, drugs, cytokines, chemokines, growth factors, hormones, proteins, and glycoproteins, cell- derived interacting motifs, biologic fluids.
- this bioactive molecule may be selected among the group consisting of: components of the extracellular matrix selected from the group consisting of proteoglycans, hyaluronic acid, collagens, elastin, fibronectin, fibrin, fibrinogen, laminins, thrombospondin;
- cell-derived growth factors e.g., platelet secretome, leukocyte secretome, platelet-derived growth factors
- - polyol compounds such as glycerol
- - plasma proteins or glycoproteins selected among albumin, globulins, transferrin, immunoglobulins;
- biologic fluids such as whole blood, bone marrow aspirate, blood serum or plasma, bone marrow serum or plasma, or cell-culture supernatants;
- hormones such as insulin, glucagon, triiodothyronine, thyroxine, steroid hormones or their antagonists;
- TPO mimetics such as TPO mimetics, TPO receptor agonists, tyrosine kinase receptor agonists, tyrosine kinase receptor inhibitors, Rho kinase inhibitors, kinase inhibitors, receptor antagonists of aryl hydrocarbons (e.g., stemregenin 1), pyrimidoindole derivatives (e.g., UM729, UM171), chemotherapeutic agents, monoclonal antibodies, polyclonal antibodies.
- aryl hydrocarbons e.g., stemregenin 1
- pyrimidoindole derivatives e.g., UM729, UM171
- chemotherapeutic agents chemotherapeutic agents, monoclonal antibodies, polyclonal antibodies.
- nucleic acids such as DNA, RNA, siRNA, RNAi and microRNA, plasmids, lentiviruses, CRISPRs;
- solid or hydrogel silk scaffolds and their combination thereof can further comprise a fluorescent marker, a contrast agent, an enzyme and/or enzymatic reaction intermediates, a luminescent substance, a chemiluminescent substance, a radio-opaque agent, a radioactive element or a conjugated or unconjugated antibody.
- the 3D silk fibroin multi-layer scaffold according to the invention further comprises a thin coating layer of silk fibroin surrounding the outer scaffold to control oxygen distribution.
- the invention further relates to the use of the 3D silk fibroin monolayer or multilayer scaffold according to the invention as ex- vivo model for supporting hematopoiesis or for the production of mature blood cells (e.g.; erythrocytes, macrophages, megakaryocytes, leukocytes, granulocytes, lymphocytes, platelets, etc.) by expansion and differentiation of HSPC or induced pluripotent stem cells or embryonic stem cells.
- mature blood cells e.g.; erythrocytes, macrophages, megakaryocytes, leukocytes, granulocytes, lymphocytes, platelets, etc.
- the present invention relates to the use of the 3D silk fibroin monolayer or multilayer scaffold of the invention as a surgical implant for supporting hematopoiesis or the production of mature blood cells in vivo.
- Said mature blood cells are preferably erythrocytes or platelets.
- a further object of the invention is a method for expansion and/or differentiation of HSPCs or induced pluripotent stem cells wherein the 3D silk fibroin monolayer or multiplayer scaffold of the invention is cultured in plate in static conditions or perfused into dynamic flow chambers with a cell culture medium comprising at least one nutrient (e.g., glucose), cytokine, growth factor, hormone, drug or prodrug, biologic fluid, plasma protein, plasma glycoprotein or a combination thereof.
- HSPCs can be retrieved from the silk scaffold.
- the methods to expand and differentiate the HSPCs of the invention may be carried out in static and dynamic culture conditions.
- the 3D silk scaffolds can be cultured into a perfusion chamber.
- the flow-through contains cytokines, growth factors, cell-derived secretome, hormones, drugs or prodrugs, biologic fluids, plasma proteins, plasma glycoproteins or a combination thereof to support differently HSPC expansion and/or differentiation.
- the flow rate can be modified to control the distribution of oxygen and nutrients, and shear stress inside the chamber.
- perfusion is performed at shear stresses of 0.05-50 dyn/cm 2 .
- the perfusion can be continuous, or intermittent (run and stop).
- the dynamic culture can be live-imaged during the perfusion.
- CD34 + HSPCs were obtained from human cord blood or human peripheral blood (purity >90%), and seeded at the concentration of 0.5-5xl0 3 cells/mm 3 in serum-free medium supplemented with 1% penicillin/streptomycin (P/S), 1% L-glutamine, 1 pM SR-1, SCF 100 ng/ml, Flt3-L 100 ng/ml, TPO 10 ng/ml.
- HSPCs were cultured in a 5% CO2 for at least 14 days in a humidified atmosphere at 37°C.
- CD34 + HSPCs were obtained from adult peripheral blood or cord blood. 2- 5xl0 3 cells/mm 3 were seeded into the silk scaffolds. Samples were differentiated for 14 days in serum-free medium supplemented with 1% P/S, 1% L-glutamine, 10 ng/mL TPO, 10 ng/mL IL-11, at 37°C in a 5% CO2 fully humidified atmosphere.
- CD34 + HSPCs were obtained from adult peripheral blood. 2-5xl0 3 cells/mm 3 were seeded into the silk scaffolds. Samples were differentiated for at least 14- 21 days in serum-free medium supplemented with 1% P/S, 1% L-glutamine, 20 ng/mL EPO, 10 ng/mL IL-3, 800 ng - 800 pg/mL holo-transferrin, at 37°C in a 5% CO2 fully humidified atmosphere.
- Mature megakaryocytes, erythrocyte, macrophages or leukocytes were seeded into the silk scaffolds and cultured, at 37 °C in a 5% CO2 fully humidified atmosphere.
- MSCs Human bone marrow mesenchymal stem cells
- Human bone marrow mesenchymal stem cells were cultured in high glucose medium supplemented with sodium pyruvate, 10% MesenCultTM MSC Stimulatory Supplement (Human), 1% L-glutamine, 1% P/S, and 1% non- essential amino acids.
- MSCs were seeded at a density of l-2xl0 3 cells/mm 3 . MSCs were cultured for at least 7 days, before starting the co-cultures.
- Osteoblasts were differentiated from human bone marrow MSCs in high glucose medium supplemented with sodium pyruvate, 10% fetal bovine serum (FBS), 1% L-glutamine, 1% P/S, 1% non-essential amino acids, 100 nM dexamethasone, 10 mM sodium P-glycerol phosphate and 50 pM ascorbic acid.
- FBS fetal bovine serum
- P/S 1% non-essential amino acids
- 100 nM dexamethasone 10 mM sodium P-glycerol phosphate and 50 pM ascorbic acid.
- Adipocytes were differentiated from human bone marrow MSCs in high glucose medium supplemented with sodium pyruvate, 1% L-glutamine, 1% P/S, 10% FBS, 0.5 mM isobutyl-methylxanthine, 1 pM dexamethasone, 10 pM insulin, 100 pM indomethacin for three days and maintained in medium with 10% FBS and 10 pM insulin for one day. The treatment was repeated three times, after which the cells were maintained in high glucose medium supplemented with 10% FBS and 10 pM insulin until day 21.
- HUVEC Human umbilical vein endothelial cells
- medium supplemented with 5% fetal bovine serum, 1% P/S, hEGF, hydrocortisone, GA- 1000, BBE, ascorbic acid.
- HUVEC were seeded at a density of 1- 2xl0 3 /mm 3 and cultured for at least 7 days, before starting the co-cultures.
- the present invention provides methods for highly customizable models of the human bone marrow characterized by their ability to produce differentiated blood cells ex-vivo from HSPCs of healthy subjects or donors with hematological diseases (e.g., genetic diseases, hematologic cancers, etc.).
- HSPCs can be from cord blood or peripheral blood or bone marrow and can be genetically modified either before or during the 3D culture. It has been observed that, i.e. the production of platelets by using the 3D silk fibroin scaffolds of the invention in the monolayer or multiplayer format (hydrogel silk scaffold alone or solid-solid silk scaffold in the outer and inner layer of a multilayer silk scaffold of the invention) is at numbers at least an order of magnitude above that achieved by known methods/scaffolds.
- the methods to expand and differentiate HSPCs by the silk scaffold of the invention may foresee an additional step of retrieval of the cells from the scaffolds, keeping them vital and functional for clinical applications.
- cells that differentiate within the silk scaffold e.g., mature platelets, mature enucleated erythrocytes
- the silk scaffold e.g., mature platelets, mature enucleated erythrocytes
- the formulation of the solution for the retrieval of the whole cell population from the scaffold of the invention consists of sodium citrate, collagenase, proteinase K, liberase and/or alginate lyase, with a source of glucose, comprises:
- the treatment is performed preferably at 37°C for 10-20 minutes.
- the present invention further relates to the use of cells released from the scaffold for carrying out morphological, functional, biochemical, and/or molecular analyses which can comprise, by way of example, one or more of the following methods:
- It is another object of the present invention a method for the production of a 3D silk fibroin multilayer scaffold comprising the following steps: i) obtaining the porous solid silk scaffold by salt leaching processing or by lyophilizing degummed silk; ii) dispersion of the stem cells of the hematopoietic lineage or progenitor cells into the solid silk scaffold, or into the different layers of solid silk scaffolds, by manual pipetting; iii) mixing the cells within the silk-based hydrogel before dispensing the solution around, or inside, the solid silk scaffold.
- the inner core is a porous solid silk scaffold obtained by salt leaching processing of 50/60-minute degummed silk (6-8%) or by lyophilizing 30/60-minute degummed silk (2-6%).
- a second layer made of a solid silk scaffold ii) is fabricated with salt leaching methods using 10/30-minute degummed silk fibroin.
- the first silk scaffold is covered by a silk hydrogel according to the composition mentioned above.
- the silk hydrogel solution is dispensed at 37°C around the first solid silk scaffold, and then crosslinked at room temperature.
- silk fibroin hydrogel is dispensed by manual pipetting.
- the hydrogel can be bio-printed around the solid silk fibroin scaffold through an extrusion-based approach with a nozzle having a caliber ranging from 18G to 27G, extrusion pressure within the range of 5-200 kPa, and printing rate within the range of 5-1,000 mm/min.
- the inner core can be the silk hydrogel according to the composition mentioned above with a solid silk scaffold as the second layer.
- the method can further comprise a step iv) of forming a coating of silk around the scaffolds, after cell seeding.
- the coating layer can form a continuous thin silk structure enclosing the scaffold to control oxygen distribution.
- the coating layer around the scaffolds can be formed using 0,5-30% w/v silk solution by any methods known to a skilled artisan, for example, without limitation, dipping, spraying, electrospinning, gel-spinning, or any combinations thereof.
- the coating is formed by dipping the scaffolds into a 1-10% w/v silk solution, followed by rapid soaking into dehydrating alcohol (e.g., methanol) and/or water-annealing.
- dehydrating alcohol e.g., methanol
- the silk scaffold is sterile.
- the sterility can be advantageously achieved by means of UV-ray sterilization.
- the above stem cells of the hematopoietic lineage are preferably mammalian cells, preferably of human origin.
- HSPCs or differentiated cells of the hematopoietic lineage can derive directly from human blood, preferably HSPCs are multipotent or pluripotent stem cells. More specifically, they can be hematopoietic stem cells (totipotent or pluripotent, including induced pluripotent stem cells and embryonic stem cells), progenitor cells (such as, for example, progenitors of the myeloid or lymphoid lineage, erythrocytes, megakaryocytes), or differentiated blood cells.
- the differentiated cells of the myeloid lineage derive from a myeloid progenitor and are selected from the group that comprises monocytes, macrophages, granulocytes, neutrophils, basophils, eosinophils, red blood cells, megakaryocytes, platelets, dendritic cells.
- the differentiated cells of the lymphoid lineage are T lymphocytes, B lymphocytes and NK cells.
- the cells are human CD34 + HSPCs from cord blood, or peripheral blood, or bone marrow, or human induced pluripotent stem cells, or embryonic stem cells.
- the cells of the hematopoietic lineage and the other co-cultured cells e.g., mesenchymal stem cells, osteoblasts, osteoclasts, osteocytes, fibroblasts, endothelial cells, endothelial progenitor cells, perivascular cells, adipocytes, neural stem cells, neurons, leukocytes, granulocytes, monocytes, lymphocytes, neutrophils, eosinophils, basophils, macrophages, erythrocytes, megakaryocytes, platelets, induced pluripotent stem cells and embryonic stem cells) can carry disease- related genetic mutations or be genetically modified (e.g., plasmid transfection, lentivirus 30 treatment, CRISP/Cas9 system).
- the cells of the hematopoietic lineage can be stained with fluorescent antibodies, conjugated or unconjugated, for the visualization of membrane antigens and/or line-specific receptors (e.g., anti-CD3, anti-CD4, anti-CD8, anti-CD34, anti-CD41, anti-CD42a, anti-CD42b, anti-CD45, anti- CD61, anti-CD117, anti-CD235, anti-cMpl) molecular markers (e.g., GFP, TOMATO), fluorescent cytoplasmic tracers (e.g., calcein, carboxyfluorescein succinimidyl ester (CFSE), CellTrac Far Red, CellTracker Deep Red), membrane tracers (e.g.
- fluorescent antibodies conjugated or unconjugated
- biotinylated or fluorescent lipids and/or phospholipids 4,4-Difluoro-l,3,5,7,8-Pentamethyl-4-Bora-3 0 , 4°-Diaza-s-Indacene, Annexin
- V fluorescent cholesterol markers
- organelles e.g. fluorescent tracers of mitochondria, endoplasmic reticulum, lysosomes, Golgi apparatus, granules
- nucleus e.g. propidium iodide, 4',6-diamidino-2-phenylindole, Hoechst
- tracers of intracellular calcium movements e.g. Fura-2 AM, Fluo-3
- Cells can be stained before or after seeding.
- LFS Low Force Stereolithography
- the model was created using software for computer-aided design and slicing.
- the printing was done using long-term non-toxic biocompatible resins.
- the flow chamber presented multiple units, each housing one single silk scaffold or a multi-layer scaffold, served by inlet and outlet ports for being connected to a perfusion pump system.
- the final device was optically clear.
- a glass window could be placed at the bottom, or at the top, of the chamber, ideal for live-cell imaging and high-resolution microscopy using long working distance objectives (e.g., confocal microscopy, multiphoton microscopy).
- Each unit of the chamber was served by independent peristaltic pumps to drive the perfusion of the cell culture medium from a reservoir to the device.
- a transfusion bag collected the flow-through.
- multiple units can be connected in series and perfused by a single common flow-through.
- the arrow in Panel D indicates the thin silk film surrounding the hydrogel.
- FIG. 2 illustrates 3D HSPC culture into silk scaffolds.
- Panel C shows the representative analysis of colony-forming units from HSPCs retrieved after 3 days of culture into the different silk scaffolds. Comparable results have been obtained from HSPCs retrieved after 1, 3, or 7 days of 3D culture.
- FIG. 3 illustrates HSPCs differentiation into erythrocytes.
- Panel A iii highlights the migration of CD68 + macrophages towards maturing erythrocytes.
- Panel B shows the flow cytometry analysis of cells retrieved after dynamic perfusion of the system. The analysis demonstrated that CD235 hlgh cells are released into the flow through.
- FIG. 4 illustrates HSPCs differentiation into megakaryocytes.
- Panel B shows the confocal microscopy reconstruction of the culture performed in a solid silk scaffold obtained by salt leaching methods and co-cultured with endothelial cells.
- Panel C shows the flow cytometry analysis of the numbers of platelets recovered after the dynamic perfusion of the scaffolds. The number of platelets has been estimated by using counting beads.
- FIG. 5 illustrates mature hematopoietic cells into the silk scaffolds.
- Panel A shows the confocal microscopy reconstruction of the 3D culture of macrophages performed into a solid silk scaffold obtained by salt leaching methods.
- Panel B shows the confocal microscopy reconstruction of the 3D culture of leukocytes performed into a solid silk scaffold obtained by lyophilization methods.
- Panel i shows the result of the activation of a colorimetric reaction developed in the HRP functionalized scaffolds incubated with 2-16 mM lactate in the presence of lactate oxidase. Lactate-free incubation was used as a negative control.
- Panel ii shows the colorimetric reaction activated by the lactate released by the same cells grown inside the 3D scaffold.
- Panel iii shows the comparison between a scaffold cultured with HSPCs and a scaffold cultured in parallel in the absence of HSPCs, as a negative control.
- panel A shows images of the dissolution process of the silk hydrogel obtained with the formulation according to the invention. Dissolution was carried out after 1, 2, 3, 5, and 7 days of culture. The sternness of released HSPCs was confirmed by colony-formation assays.
- Panel B shows the flow cytometry analysis of CD34 + cells retrieved from the silk hydrogel after 3 days of culture into the scaffold.
- Panel C shows the colony-forming units formed by HSPCs retrieved from the silk hydrogel after 3 days of culture into the scaffold.
- Silk fibroin aqueous solution was obtained from Bombyx mori silkworm cocoons. To prepare pure silk fibroin solution, silkworm cocoons undergo a degumming procedure to separate the silk fibroin fibers from the sericin glue.
- the molecular weight distribution of silk fibroin chains varies depending on the extraction and purification process utilized to prepare the protein polymer (Sahoo et al., 2020), [10]). Increased degumming time progressively degrades the silk chains resulting in a decrease in the molecular weight from >200 kDa to ⁇ 90 kDa (experimentally confirmed by Asymmetric Flow Field-Flow Fractionation).
- dewormed cocoons were boiled for degumming for 10, 20, 30, 40, 50, or 60 minutes in 0.02 M Na2COa solution at a weight to volume ratio of 5 g to 2 L.
- the fibers were rinsed for 20 min for three times in ultrapure water and dried overnight.
- the dried fibers were solubilized for 4h at 60°C in LiBr (>9.3 M) at a weight-to-volume ratio of 3 g-12 mL.
- the solubilized silk solution was dialyzed against distilled water using a Slide-A-Lyzer cassette with a 3500 MW cut-off for three days and changing the water a total of eight times.
- the silk solution was centrifuged at maximum speed for 10 min to remove large particulates and stored at 4°C.
- the concentration of the silk solution was determined by drying a known volume of the solution and massing the remaining solids.
- NaCh particles (approximately >300 pm in diameter) were sifted into a silk solution (8% w/v) in a ratio of 1 mL silk/2 g salt, within a molding system (e.g., petri dish, silicon chamber).
- the scaffolds were then placed at room temperature for 48 hours and then soaked in distilled water for 48 hours to leach out the salt particles.
- the scaffolds were sterilized in 70% ethanol and finally rinsed five times in PBS over 24 hours.
- the silk solution (2% w/v) was cast within a molding system and incubated at -80°C for one day. The frozen solution was then lyophilized for 48-72 hours at -56°C. The lyophilized scaffolds were subsequently autoclaved for 20 minutes to induce the P-sheet formation and stabilize the silk matrix.
- Hydrogel silk scaffold
- Silk hydrogels were composed of:
- the temperature of the silk hydrogel formulation is 37°C when the cells are to be added.
- Silk hydrogels were produced at 37°C. After deposition, the silk hydrogel could be crosslinked with a CaCh solution for a minimum of 10 minutes.
- the crosslinking solution contains 0.05M CaCh dissolved in a buffer solution containing 150 mM NaCl, 6 mM KC1, 1 mM MgCh, 5 mM glucose, 10 mM HEPES.
- Solid and hydrogel silk scaffolds could be assembled into 3D multi-layer tissues that mimic the structure and composition of the different bone marrow microenvironments .
- the inner core is a porous solid silk scaffold obtained by salt leaching processing of 50 minutes degummed silk (8%) ( Figure 1A) or by lyophilizing 30 minutes degummed silk (2%) ( Figure IB).
- the second layer of the tissue model can be fabricated with salt leaching methods using 30 minutes degummed silk fibroin (Figure 1A) or 50 minutes degummed silk fibroin (Figure IB).
- a third layer of the tissue model can be fabricated with salt leaching methods using 10 minutes degummed silk fibroin ( Figure IB).
- the silk hydrogel solution is dispensed at 37°C around the first solid silk scaffold, and then crosslinked at room temperature (Figure 1C).
- Silk fibroin hydrogel was dispensed by manual pipetting.
- the hydrogel can also be bio-printed around the solid silk fibroin scaffold through an extrusion-based approach with a nozzle having a caliber of 20G, extrusion pressure of 12 kPa, and printing rate of of 500 mm/min.
- a silk film can be layers outside the silk hydrogel (Figure ID).
- the silk film is formed by deeping the multi-layer scaffold into a 2% solution of 30 minutes degummed silk. The system is then soaked into methanol for 2 seconds to allow rapid P-sheet formation and consequent solidification.
- Salt-leaching rectangular shape, 200 mm 3
- Lyophilized cylindrical shape, 400 mm 3
- HSCPs have been co-cultured with human mesenchymal stem cells (Figure 2A).
- Mesenchymal stem cells were positioned either in the same scaffold of HSPCs or inside the second layer.
- the 3D culture was monitored and digitally reconstructed by confocal imaging equipped with a temperature-controlled incubator in a humidified atmosphere and 5% CO2. At the end of the culture, more than 95% of the cells survived in all tested conditions.
- HSPC proliferation was analyzed by measuring the number of cells/mm 3 by confocal 3D reconstruction.
- the sternness was determined via colony forming unit (CFU) assays.
- CFU colony forming unit
- Cells were retrieved from the silk scaffolds by manual pipetting on days 1, 3, and 7 of 3D culture.
- the lyophilized silk scaffold allowed a more efficient recovery, with nearly >90% of the cells being pipetted out of the 3D matrix ( Figure 2B).
- Cells were then plated in a methylcellulose-based medium supplemented with penicillin and streptomycin. Two weeks after plating, colonies were identified according to standard morphological criteria and counted in a blinded fashion (Figure 2C).
- a significantly increased number of colonies were generated in methylcellulose assays from the 3D cultures with respect to 2D liquid cultures, performed in parallel.
- the number of BFU-E and CFU-GEMM colonies was significantly higher thus demonstrating retained sternness and differentiation capability.
- HSPCs were cultured for 7 days in a stem cell medium and then differentiated into erythrocytes or megakaryocytes by switching the culture medium, according to the above-described methods.
- the imaging of the 3D culture demonstrated efficient cell differentiation into enucleated erythrocytes or platelets, respectively.
- the medium was changed every two days to ensure enough moisture in the system.
- the medium was pumped continuously into the system over the course of the culture, for up to 4 weeks, changing the medium reservoir based on the experimental conditions.
- HSPCs co-culture with osteoblasts, seeded into the second layer of the scaffold demonstrated retained cell proliferation and stem cell profile, even in a medium containing differentiating cytokines (e.g., thrombopoietin).
- cytokines e.g., thrombopoietin
- mesenchymal stem cells and a megakaryocytic differentiating medium we observed the proliferation of fully mature megakaryocytes forming increased numbers of platelets with respect to standard liquid cultures.
- HSPCs were seeded into a 30-minute degummed silk scaffold obtained by salt leaching (8% silk solution) and functionalized with fibronectin.
- the scaffold was filled with enough medium to keep it constantly wet.
- Cell differentiation was analyzed by means of different microscopy and flow cytometry approaches.
- the differentiation patterns were similar in the early-intermediate phases of erythropoiesis, as demonstrated by a comparable percentage of CD235 + CD71 + cells.
- a striking difference could be observed in the terminal phase of maturation. Indeed, the amount of CD235 + CD71‘ cells was substantially higher than the 3D cultured cells, suggesting that our silk scaffold effectively supported enucleation.
- enucleated CD235 + CD71‘ cells were mainly localized at the periphery of the cellular aggregate or next to co-cultured CD68 + macrophage ( Figure 3A iii). After two weeks of static culture, the scaffold has been dynamically perfused to assess the effect of laminar flow on erythrocyte terminal differentiation, particularly during the enucleation phase.
- Example 4 Megakaryocyte differentiation and platelet production
- Bone marrow cell behavior is regulated by cell-intrinsic and cell-extrinsic forces.
- Mechanical forces determine mesenchymal stem cells fate (e.g., differentiation into the osteoblast or adipocyte-committed lineage) as well as remodeling of the ECM components.
- mesenchymal stem cell behavior in the niche by changing the mechanical properties of the silk.
- the scaffolds obtained from the shortest degumming time (10 minutes) exhibited the highest rigidity vs 30- and 50- minute degumming time, as demonstrated by atomic force microscopy-based nanoindentation.
- the resulting structure confers high mechanical performance and resistance to promote osteogenic induction to human bone marrow mesenchymal stem cells.
- the second scaffold was obtained using 30-minute degummed silk fibroin. This softer model supported mesenchymal stem cell growth and deposition of ECM components.
- Multi-layer scaffolds were inserted into the 3D printed flow chamber, connected to a syringe pump at the inlet and to a gas- permeable collection bag, containing anticoagulant, at the outlet, and placed into an incubator at 37°C and 5% CO2.
- the porous silk structure of the scaffolds ensured immediate binding at the interface of the two layers that remained discrete but interconnected entities.
- Samples have been fed continuously with the culture medium to ensure oxygenation and transport of nutrients through the scaffold. The flow-through is distributed homogeneously within all the layers.
- Platelet count at the outlet was assessed by flow cytometry by mixing samples with counting beads. Platelets were identified based on the expression of CD41 and CD42b surface markers. The comparison of platelet counts among the different test conditions demonstrated a significant increase in the yield of platelets from megakaryocytes into multi-layers silk scaffold containing mesenchymal stem cells (Figure 4C) or endothelial cells, with respect to megakaryocytes alone (*p ⁇ 0.05).
- Erythrocytes, megakaryocytes, macrophages, or leukocytes were seeded into a 30- minute degummed silk scaffold obtained by salt leaching (8% silk solution) or by lyophilization (2% silk solution) and functionalized with fibronectin.
- the scaffold was filled with enough medium to keep it constantly wet. Cells were imaged by means of confocal microscopy (Figure 5).
- Bioactive silk scaffolds dosage of lactate released by the cells during culture
- HRP horseradish peroxidase
- the functionalized scaffolds were also tested in the presence of hematopoietic progenitors for dosing molecules released during the 3D culture by the cells themselves, without the need for manipulating the scaffold.
- lactate a product of glycolysis, indicative of an active cellular metabolism and whose variation can be indicative of alterations in HSPC proliferation and/or differentiation.
- DHBS 3,5-dichloro-2-hydroxybenzenesulfonate
- 4-aminoantipyrine (4-AAP) was dispensed onto the scaffolds.
- the reagents can be added directly to the silk solution before producing the scaffolds.
- the bioactivity of the preparation was confirmed by the activation of a colorimetric reaction following incubation with lactate (2-16 mM) ( Figure 6 i). Lactate-free incubation was used as a negative control. The presence of increasing concentrations of lactate released by the cells was detected during the culture of the bioprinted 3D scaffold ( Figure 6 ii, iii). The specificity of the reaction was confirmed by treating the sample with the lactate dehydrogenase inhibitor.
- Example 7 Dissolution of the silk hydrogel
- HSPCs were cultured for 7 days in a stem medium and then incubated in the dissolution solution (according to the invention), at 37°C for 20 minutes ( Figure 7A).
- the cells were then centrifuged at 1,200 rpm for 10 minutes, washed in a physiological solution, and used in the experimental assays.
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Developmental Biology & Embryology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The present invention relates to silk fibroin-based scaffolds suitable for supporting the 3D culture of human hematopoietic stem and progenitor cells and/or the production of blood cells ex-vivo, and methods for producing the same.
Description
TITLE
METHODS FOR HEMATOPOIETIC STEM AND PROGENITOR CELL EXPANSION AND DIFFERENTIATION IN THREE-DIMENSIONAL SILK SCAFFOLDS AND USES THEREOF
ABSTRACT
The present invention relates to silk fibroin-based scaffolds suitable for supporting the 3D culture of human hematopoietic stem and progenitor cells and/or the production of blood cells ex-vivo, and methods for producing the same.
BACKGROUND
Hematopoiesis occurs in the bone marrow. Hematopoietic stem and progenitor cell (HSPC) fate decisions are dependent on signals from specialized microenvironments in the bone marrow, termed niches, three-dimensional (3D) environments that comprise cellular, chemical, and physical elements.
Most experimental approaches to study human hematopoiesis use bidimensional culture techniques with poor control over cell sternness and differentiation capability. Tissue-engineering approaches have been developed to create 3D-functional mimics of the native organs (Di Buduo et al., 2021 [1]). The bone marrow represents a challenging tissue to reproduce because its structure and composition confer unique biochemical and mechanical features to control HSPC quiescence, expansion, and differentiation.
Reproducing the human bone marrow niche is instrumental to answer the growing demand for human blood cells production ex-vivo either for fundamental studies or for clinical applications in the fields of transfusion and regenerative medicine, and bone marrow transplantation: models that recapitulate the complexity of human bone marrow can foster mechanistic studies of normal and malignant hematopoiesis and the validation of novel pharmacological therapies.
HSPCs transplantation is the leading clinical application of cell-based therapies. Successful transplantations require a considerable amount of high-quality HSPCs to reconstitute long-term hematopoiesis. However,
present-day procedures for harvesting and manipulating these cells cannot guarantee optimal therapeutic yield nor the quality of transplantable HSPCs. HSPC processing in conditions that reproduce their native bone marrow environment may lead to improvements in HSPC function and engraftment outcomes. more than 100 million units of blood are reported to be collected worldwide every year. Nevertheless, in no country does the contribution of volunteers succeed in coping with the growing demand, making it necessary to create alternative methods to produce blood cells. Ex-vivo manufacturing of mature blood cell products (i.e., erythrocytes and platelets) is becoming an increasingly attractive approach for both basic research and clinical applications (e.g., transfusion medicine).
In vitro, culture conditions miss the bone marrow’s physical environment, which drives either HSPC self-renewal or differentiation into mature blood cells in vivo. In most of the current in vitro culture systems, HSPCs lose sternness a few hours after starting the culture, while differentiated blood cells look immature. For example, erythrocytes appear macrocytic, and platelets appear larger with immature granules. Also, it is known that cultured erythrocyte progenitors fail the enucleation process, while megakaryocytes of any origin produce fewer platelets per single cell than they do in vivo [1].
3D bone marrow organoids have been developed, though these systems allow the development of a self-made bone marrow microenvironment useful for mechanistic studies with limited possibility of experimental control and hampered cell harvesting and usage for clinical application (Khan et al., 2022 [2]).
3D scaffolds made of different types of organic (e.g., PEG, PCL, PU) and inorganic (e.g., HAp) biomaterials have been proposed to reproduce the 3D architecture as well as mechanical properties, nanopatterning, and topography of the native bone marrow. Also, their biofunctionalization through surface coatings, absorption, and/or covalent conjugation of ECM-derived molecules or cell-interacting motifs (e.g., collagen, fibronectin, laminin) has been
proposed. Though, they could only support targeted HSPCs functions and concise experiments that hindered the possibility of transferring a single technique/approach into wide applications [1].
Shear forces occurring by fluid flow and gradients of soluble factors, such as growth factors or cytokines, play a role in controlling HSPC behavior. The emergence of bone marrow-on-chip technologies has empowered the development of more complex models of the niche. These systems were able to provide a hydrodynamic shear supporting dynamic cell culture, but with low efficiency in terms of cell numbers because of their nano/micro-scale nature which cannot support large-scale approaches (e.g., industrial application, implementation into clinical processes).
Overall, none of the available systems have been validated for supporting at the same time long-term HSPC culture and/or their programmable differentiation into different blood lineages.
For applications aiming to mimic different natural processes of the niche, the complexity of the system must be reduced to the essentials to be easily modeled according to the scientific question to be addressed.
In the past 10 years, the present inventors’ expertise in modeling silk fibroin biomaterial has led to the development of early models of silk-bone marrow able to produce human platelets by in vitro differentiated megakaryocytes from cord blood-derived HSPCs to provide proof-of-concept evidence of their applicability for transfusion medicine.
The first generation of silk-based bone marrow models developed by the inventors (Pallotta et al., 2011 [3]; Di Buduo et al., 2015 [4], international patent application WO2016/022834 Al [5]) were composed of porous silk tubes, mimicking vessels, surrounded by a 3D matrix to allow the recording of megakaryocyte functions (i.e. , migration, proplatelet formation) in response to variations in extracellular matrix components, surface topography and stiffness, and co-culture with endothelial cells. This method could produce human platelets, but not other blood cells, and cannot support long-term cultures. This system demonstrated the fundamental qualities of silk fibroin
for studying thrombopoiesis, such as non-thrombogenicity and the possibility to entrap different molecules while retaining their bioactivity. A limitation of this model was the use of custom-made chambers and silk tubes whose production could not be standardized or scaled up easily to guarantee clinical applications.
The second generation of silk-bone marrow models developed by the inventors (Di Buduo et al., 2017 [6], Tozzi et al., 2018 [7]) consisted of a scaled-up version intended to house a larger number of in vztro-derived megakaryocytes producing platelets for functional studies. The flow chambers were made of research-grade silicon or biomaterial, holding a silk sponge, prepared with salt leaching methods [6] or by lyophilization [7], and functionalized with extracellular matrix components (fibronectin [6], collagen IV [7]). Perfusion of the chambers allowed the recovery of platelets when the silk sponges were cultured with cord blood-derived megakaryocytes.
A miniaturized system (Di Buduo et al., 2021 [8]; international patent application WO2021/11383OA1 [9]) could produce measurable numbers of platelets by megakaryocytes differentiated in vitro by HSPC derived from adult peripheral blood.
None of these systems was designed to produce blood cells other than platelets and cannot support long-term cultures. Indeed, all these systems have been validated by culturing megakaryocytes for a few hours ([3], [4], [6], [7]) or a few days [8]. HSPC differentiation into megakaryocytes was carried out in classic Petri dishes.
As a result, the efficiency of the systems was limited because: prior art methods could not support long-term HSCPs expansion and retrieval or differentiation into different blood cell lineages. prior art methods could not support simultaneous long-term co-culture of HSPCs with other non-hematopoietic cell types (e.g., mesenchymal stem cells, osteoblasts, osteoclasts, osteocytes, fibroblasts, endothelial cells, perivascular cells, adipocytes, neurons). prior art methods could not support simultaneous long-term co-culture
of HSPCs with mature blood cells (e.g., leukocytes, granulocytes, monocytes, lymphocytes, neutrophils, eosinophils, basophils, macrophages, erythrocytes, megakaryocytes, and platelets). prior art methods could not allow control over oxygen distribution within the culture.
In view of the above drawbacks, the present invention provides 3D silk scaffolds and methods for: human HSPC culture and expansion while keeping sternness in 3D silk scaffold. The culture method allows cell recovery for performing functional studies (e.g., colony formation assays, in situ differentiation). human HSPC differentiation into red blood cells. The culture methods allow the spontaneous formation of erythroblastic islands that support final erythrocyte maturation and enucleation. human HSPC differentiation into platelet-forming megakaryocytes. The improved culture method allows the production of an increased number of platelets with improved functionality with respect to previous methods and 2D liquid culture. production of multi-layer scaffolds for the co-culture of HSPCs with mesenchymal stem cells, osteoblasts, osteoclasts, osteocytes, fibroblasts, endothelial cells, perivascular cells, adipocytes, neurons, leukocytes, granulocytes, monocytes, lymphocytes, neutrophils, eosinophils, basophils, macrophages, erythrocytes, platelets, megakaryocytes alone or in combination, to support improved HSPC differentiation. The stiffness of the silk scaffold to guide cell function may be regulated. silk scaffold perfusion into programmable flow chambers with a culture medium at different flow rates and timing (e.g.; continuous, intermittent). The composition of the perfused medium can be varied to guide HSPC quiescence, expansion or differentiation.
SUMMARY OF THE INVENTION
The present invention relates to a 3D silk fibroin scaffold for HSPC culture
and differentiation into mature blood cells. A multi-layer scaffold can be assembled comprising at least two interconnected silk scaffolds: i) an inner core made of a porous solid silk fibroin scaffold or of a silk fibroin hydrogel comprising stem cells of the hematopoietic lineage; ii) at least one silk fibroin scaffold surrounding the inner scaffold i) made of silk fibroin hydrogel or porous solid silk fibroin scaffold comprising differentiated or undifferentiated cells selected between hematopoietic stem cells, or hematopoietic progenitor cells, mature blood cells and/or other non- hematopoietic cell types (e.g., mesenchymal stem cells, osteoblasts, osteoclasts, osteocytes, fibroblasts, endothelial cells, perivascular cells, adipocytes, neurons).
Solid and hydrogel silk scaffolds could be assembled into 3D multi-layer tissues that mimic the structure and composition of the different bone marrow microenvironments. The minimum number of layers is two. As many layers as needed can be added based on the experimental needs.
Silk fibroin can be of a natural origin, such as, for example, fibroin produced by arthropods such as silkworms (e.g., Bombyx mori, Anthereae pernyi) or spiders (e.g., Nephila clavipes, Araneus diadematus). Alternatively, the silk fibroin can be of a recombinant origin, such as for example the fibroin produced by engineered systems (e.g.; bacteria, yeast). Alternatively, fibroin can be reconstituted from a lyophilized formulation. Silk fibroin can be chemically modified. According to a preferred embodiment, silk fibroin is extracted from Bombyx mori silkworm cocoons.
In some embodiments, resulting silk-based scaffolds can be arranged into predetermined patterns (e.g., cylindrical, rectangular, spherical, hexagonal) for controlled localization of at least two different cell types within the multi-layer scaffold.
In a preferred embodiment of the 3D silk fibroin multi-layer scaffold of the invention, the inner scaffold comprises stem cells of the hematopoietic lineage. According to another embodiment of the 3D silk fibroin multi-layer scaffold according to the invention, the undifferentiated cells of the silk fibroin scaffold
ii) are stem and progenitor cells of the hematopoietic lineage, mesenchymal stem cells, endothelial progenitor cells, neural stem cells, induced pluripotent stem cells or embryonic stem cells, when the 3D silk fibroin multi-layer scaffold further comprises one or more additional silk layer.
In a preferred embodiment, said stem cells of the hematopoietic lineage are HSPCs. In another preferred embodiment, said stem cells of hematopoietic lineage are derived from induced pluripotent stem cells. In a further preferred embodiment said stem cells of hematopoietic lineage are derived from embryonic-derived cells.
In a preferred embodiment, the solid silk scaffold, the hydrogel scaffold, or at least one of the two layers of the multi-layers scaffold comprises a cell component selected in the range of 0.01-100xl03 cells/mm3.
In a preferred embodiment, the silk scaffold volume is a minimum of 3 mm3. In another preferred embodiment, the other layer (or layers) ii) comprises differentiated cells belonging to the category selected among mammalian osteoblasts, osteoclasts, osteocytes, fibroblasts, endothelial cells, perivascular cells, adipocytes, neurons, leukocytes, granulocytes, monocytes, lymphocytes, neutrophils, eosinophils, basophils, macrophages, erythrocytes, platelets, megakaryocytes and/or undifferentiated cells belonging to the category selected among stem and progenitor cells of the hematopoietic lineage, mesenchymal stem cells, endothelial progenitor cells, neural stem cells, induced pluripotent stem cells or embryonic stem cells, in the range of 0.1- lOOxlO3 cells/mm3.
In another preferred embodiment, at least two different cell types can be cocultured in the same or different layer.
According to a preferred embodiment of the 3D silk fibroin multi-layer scaffold of the invention, the porous solid silk fibroin scaffold comprises interconnected pores having a diameter > 5 pm. The porosity ensures the exchange of soluble factors and the possibility of cell migration among different compartments.
The scaffolds according to the present invention were tested by culturing
different cell types, such as human blood cancer cell lines, human HSPCs, murine HSPCs, human induced pluripotent stem cells, human and murine bone marrow cells, human and mouse mature blood cells, thus showing a wide versatility of use. Before seeding HSPCs, the silk fibroin scaffolds and hydrogels, alone or in combination, can be enriched with a different combination of differentiated cells belonging to the category selected among mammalian osteoblasts, osteoclasts, osteocytes, fibroblasts, endothelial cells, perivascular cells, adipocytes, neurons, leukocytes, granulocytes, monocytes, lymphocytes, neutrophils, eosinophils, basophils, macrophages, erythrocytes, platelets, megakaryocytes and/or undifferentiated cells belonging to the category selected among stem cells of the hematopoietic lineage, mesenchymal stem cells, endothelial progenitor cells, neural stem cells, induced pluripotent stem cells or embryonic stem cells, (alone or in different combinations).
The elasticity and viscosity of silk fibroin can be adjusted depending on the methods used for the fibroin extraction.
Oxygen distribution inside the scaffold can be controlled by varying silk fibroin composition and assembly at the surface of the scaffolds and/or hydrogels.
To obtain the solid silk scaffold NaCh particles (approximately >300 pm in diameter) were sifted into a silk solution (2-20% w/v) in a ratio of 1 mL silk/2 g salt, within a molding system (e.g., petri dish, silicon chamber). The scaffolds were then placed at room temperature for 48 hours and then soaked in distilled water for 48 hours to leach out the salt particles. The scaffolds were sterilized in 70% ethanol and finally rinsed five times in phosphate-buffered saline (PBS) over 24 hours.
Alternatively, the silk solution (1-20% w/v) was cast within the molding system and incubated at -80°C for one day. The frozen solution was then lyophilized for 48-72 hours at -56/-80°C. The lyophilized scaffolds were subsequently autoclaved for 20 minutes to induce the P-sheet formation and stabilize the silk matrix.
Both types of silk scaffolds were characterized by confocal microscopy and
scanning electron microscopy. Depending on silk fibroin degumming time (10, 20, 30, 40, 50, or 60 minutes) and final concentration (1-20%), and on P-sheet inducing parameters (salt leaching or lyophilization), the bulk region of these solid scaffolds can be prepared with control over a variety of factors, including, but not limited to, pore sizes and morphologies, mechanical properties, degradation rates, and any combinations thereof.
The hydrogel silk scaffold is composed of:
- silk fibroin 0.5% -35% weight/volume (w/v)
- gelatin or derivatives thereof 5-20% w/v
- alginic acid or derivatives thereof 0.5-2% w/v
- glucose or analogues thereof 3-4% w/v
- controlled density solution 1-3% w/v
- buffer 4-6% w/v
- albumin 0.01-1% w/v
- saline buffer solution up to 100% wherein the gelatin and alginic acid or their derivatives are present in a reciprocal ratio ranging from about 10:1 to about 20:1; wherein the silk fibroin and the gelatin are present in a reciprocal ratio ranging from 15 about 1:5 to about 1:0.5; suitable for mixing with hematopoietic cells. The cell component can be part of the initial formulation. The temperature of the silk hydrogel formulation is 37°C when the cells are to be added.
Silk hydrogels were produced at 37°C. After deposition, the silk hydrogel could be crosslinked with a CaCh solution for a minimum of 10 minutes. The crosslinking solution preferably contains 0.05-0.1 M CaCh dissolved in a buffer solution containing NaCl, KC1, MgCh, glucose, and HEPES.
In a preferred embodiment, the saline buffer solution contains: 150 mM NaCl, 6 mM KC1, 1 mM MgCh, 10 mM HEPES.
In a preferred embodiment of the silk fibroin hydrogel formulation according to the invention, the gelatin and alginic acid or their derivatives are present in a reciprocal ratio of about 15: 1.
Again, in accordance with a preferred embodiment of the silk fibroin hydrogel
formulation according to the invention, the fibroin and gelatin or its derivatives are present in a reciprocal ratio equal to about 1:5 or about 1:2 or 1: 0.5.
Optionally, the silk fibroin is dissolved in a solution comprising one or more ion sources selected from the group consisting of alkaline or alkaline earth metal 10 chlorides, such as for example MgCh, CaCh, NaCl, KC1.
The gelatin used in the silk fibroin hydrogel formulation according to the invention can be type A (acid hydrolysis) or type B (alkaline hydrolysis). Preferably, gelatin is of type A.
According to a preferred embodiment of the formulation according to the invention, the gelatin derivatives are selected from the group consisting of gelatin conjugated with chitosan, gelatin-poly(DL-lactide), gelatin modified with PEG, gelatin thiolates, DNA-gelatin nanospheres, gelatin nanoparticles, gelatin-coated fluorescent maghemite nanoparticles, gelatin-coated fluorescent polymethacrylic acid nanoparticles (FPMAAG), supramolecular gelatin nanoparticles coated with quantum dots, gelatin nanoparticles coated with iron oxide, gelatin methacrylate, xanthan gum human gelatin, recombinant gelatin, gelatin marked with fluorescent molecules.
According to a preferred embodiment of the formulation, the alginic acid derivatives are salts with alkaline and alkaline earth metals selected from the group consisting of sodium alginate, calcium alginate, magnesium alginate, and potassium alginate. Alternatively, methacrylate alginate can be used to produce photopolymerizable hydrogels in the presence of soluble photoinitiators. According to preferred embodiments of the invention, the glucose analogues are selected from the group consisting of disaccharides, stereoisomers, isomers, epimers, alditols or acids of glucose, precursors or products deriving from the glucose metabolism. Glucose analogues within the context of the present invention refer to metabolites that can be transported within the cell, become part of the glycolysis cycle, and metabolized.
Other sugars, such as xylose, do not form part of the present invention as they are not capable of entering the cell via glucose transporters and cannot enter the glycolysis cycle. The cells are therefore not capable of metabolizing them.
By way of example, the glucose analogues can be selected from the group consisting of: D-glucose, L-glucose, lactose, sucrose, trehalose, cellobiose, melibiose, maltose (disaccharides), mannitol, galactose, mannose, fructose (epimers), allose, altrose (stereoisomers), gluconic acid, glucuronic acid (acids), arabinose, glycerol, pyruvate, glucose 1-phosphate, glucose 6- phosphate, lactate, malate, phosphoglycerate, succinate (precursors or derivatives of the glucose metabolism), sorbitol (alditol). The glucose can also be replaced by fluorescent analogues that allow the glucose transportation to be monitored (e.g. 2-(N-(7-nitrobenz-2-oxa-l,3-diazol-4-yl)amino)-2- deoxyglucose) or analogues that inhibit the glycolytic metabolism (e.g. 2- deoxy-d-glucose).
In further preferred embodiments of the invention, the controlled density solution is a controlled density solution selected from the group consisting of Percoll® (colloidal silica particles of 15-30 nm in diameter (23% w/w in water) coated with polyvinylpyrrolidone), Ficoll® (sucrose and epichlorohydrin copolymer), colloidal silica, copolymers (e.g. sucrose and epichlorohydrin), hydrophilic polysaccharides (e.g. sucrose), high-molecular-weight synthetic polymers (e.g. Polysucrose®). The controlled density solution is preferably Percoll®.
The choice of the controlled density solution depends on the degree of density to be attributed to the formulation for optimizing the distribution of cells in the suspension and eventually preserving their vitality during the printing process. Further, preferred embodiments of the hydrogel formulation according to the invention provide that the buffer be an organic or mineral buffer selected from the group consisting of: MES, ADA, ACES, PIPES, MOPSO, Bis-6Tris Propane, BES, MOPS, TES, HEPES, DIPSO, MOBS, TAPSO, HEPPSO, POPSO, EPPS, Tricine, Gly-Gly, Bicine, HEPBS, TAPS, AMPD, TABS, AMPSO, CHES, CAPSO, AMP, CAPS and CABS. The buffer is preferably HEPES (4-2- hydroxyethyl-l-piperazinyl-ethanesulfonic acid) which has strong buffering power.
Based on the culture conditions required for ensuring vitality and functionality
of the cell type being mixed with the hydrogel, the ideal buffer system is selected that allows the desired pH, the subsequent culture, and in any type of manipulation and/or analysis of the scaffolds in an uncontrolled CO2 atmosphere.
The presence of the buffer, for example, is an advantage during the deposition process. In this way, it is possible to keep the cells viable as they are maintained at a physiological pH, even outside of the incubator.
The silk hydrogel formulation according to the invention always maintains a physiological pH. Without a buffer, the formulation can lose its physiological pH and this results in a reduction in cell vitality /functionality.
In a preferred embodiment, the formulation according to the invention has the following composition: silk fibroin 8% w/v gelatin 15% w/v alginic acid 1% w/v glucose 3.5% w/v
Percoll® 2.5% w/v
HEPES 5% w/v saline buffer solution up to 100% albumin 0.1% w/v
Solid and hydrogel silk scaffolds could be assembled into 3D multilayertissues that mimic the structure and composition of the different bone marrow microenvironments. The minimum number of layers is two. As many layers as needed can be added based on the experimental needs.
According to a preferred embodiment, the central core is a porous solid silk scaffold obtained by salt leaching processing of 50/60-minute degummed silk (6-8%) or by lyophilizing 30/60-minute degummed silk (2-6%). The second layer of the tissue model is fabricated with salt leaching methods using 10/30- minute degummed silk fibroin. Alternatively, the first silk scaffold is covered by a silk hydrogel according to the composition mentioned above. The silk hydrogel solution is dispensed at 37 °C around the first solid silk scaffold, and
then crosslinked at room temperature. According to a preferred embodiment, silk fibroin hydrogel is dispensed by manual pipetting. Alternatively, the hydrogel can be bio-printed around the solid silk fibroin scaffold through an extrusion-based approach with a nozzle having a caliber ranging from 18G to 27G, extrusion pressure within the range of 5-200 kPa, and printing rate within the range of 5-1,000 mm/min.
According to a preferred embodiment the multi-layer model, comprise at least two interconnected silk scaffolds, wherein at least one scaffold partially surrounds the other, and at least one of the scaffolds comprises interconnected pores, wherein pores have a diameter >5 pm.
The present invention further relates to the use of the scaffolds described above as an ex-vivo model for keeping sternness, supporting hematopoiesis or for the production of mature blood cells (including erythrocytes, macrophages, megakaryocytes, leukocytes, granulocytes, lymphocytes, and platelets) through the use of growth factors or mediums that maintain the sternness or promote cell differentiation. The cells retrieved from the scaffolds may be used for morphological, functional characterization (e.g., expression of lineagedifferentiation markers; differentiation assays), and clinical applications (e.g., transfusion, transplant).
Further, the invention relates to the use of the scaffold described above as a surgical implant for keeping sternness, supporting hematopoiesis or for the production of erythrocytes, macrophages, megakaryocytes, leukocytes, granulocytes, lymphocytes, platelets, and other blood cells in vivo.
In a preferred embodiment of the invention, said implant further comprises one or more drugs, hormones, growth, or differentiation factors that can be released in situ.
In some embodiments, the silk fibroin scaffolds, and hydrogels of the invention can be functionalized with bioactive molecules (i.e., enzymes, substrates and intermediates of enzymatic reactions, extracellular matrices, drugs, cytokines, chemokines, growth factors, hormones, proteins, and glycoproteins, cell- derived interacting motifs, biologic fluids).
In particular, this bioactive molecule may be selected among the group consisting of: components of the extracellular matrix selected from the group consisting of proteoglycans, hyaluronic acid, collagens, elastin, fibronectin, fibrin, fibrinogen, laminins, thrombospondin;
- growth factors, cytokines, and chemokines, interleukins, CSF-1, G-CSF, M- CSF, GM-CSF, SCF, FLT3-L, TPO, EPO, SDF-la; TGF- 1, TNFa, VEGF, FGF, Notch ligands, WNT, angiopoietin-1, BMP, IGF-2 and fragments or variants thereof;
- cellular secretome and cell-derived growth factors (e.g., platelet secretome, leukocyte secretome, platelet-derived growth factors);
- polyol compounds such as glycerol;
- plasma proteins or glycoproteins, selected among albumin, globulins, transferrin, immunoglobulins;
- lipids, cholesterol and lipoproteins;
- biologic fluids such as whole blood, bone marrow aspirate, blood serum or plasma, bone marrow serum or plasma, or cell-culture supernatants;
- cell-derived interacting motifs, antigens, conjugated or unconjugated antibodies, or their fragments such as CDRs or epitopes;
- hormones, such as insulin, glucagon, triiodothyronine, thyroxine, steroid hormones or their antagonists;
- drugs or prodrugs, such as TPO mimetics, TPO receptor agonists, tyrosine kinase receptor agonists, tyrosine kinase receptor inhibitors, Rho kinase inhibitors, kinase inhibitors, receptor antagonists of aryl hydrocarbons (e.g., stemregenin 1), pyrimidoindole derivatives (e.g., UM729, UM171), chemotherapeutic agents, monoclonal antibodies, polyclonal antibodies.
- nucleic acids, such as DNA, RNA, siRNA, RNAi and microRNA, plasmids, lentiviruses, CRISPRs;
- enzymes, such as horseradish peroxidase, and/or their substrates or intermediates of enzymatic reactions.
- toxins.
According to a further embodiment of the present invention, solid or hydrogel silk scaffolds and their combination thereof can further comprise a fluorescent marker, a contrast agent, an enzyme and/or enzymatic reaction intermediates, a luminescent substance, a chemiluminescent substance, a radio-opaque agent, a radioactive element or a conjugated or unconjugated antibody.
According to an alternative embodiment, the 3D silk fibroin multi-layer scaffold according to the invention further comprises a thin coating layer of silk fibroin surrounding the outer scaffold to control oxygen distribution.
The invention further relates to the use of the 3D silk fibroin monolayer or multilayer scaffold according to the invention as ex- vivo model for supporting hematopoiesis or for the production of mature blood cells (e.g.; erythrocytes, macrophages, megakaryocytes, leukocytes, granulocytes, lymphocytes, platelets, etc.) by expansion and differentiation of HSPC or induced pluripotent stem cells or embryonic stem cells.
According to another aspect the present invention relates to the use of the 3D silk fibroin monolayer or multilayer scaffold of the invention as a surgical implant for supporting hematopoiesis or the production of mature blood cells in vivo. Said mature blood cells are preferably erythrocytes or platelets.
A further object of the invention is a method for expansion and/or differentiation of HSPCs or induced pluripotent stem cells wherein the 3D silk fibroin monolayer or multiplayer scaffold of the invention is cultured in plate in static conditions or perfused into dynamic flow chambers with a cell culture medium comprising at least one nutrient (e.g., glucose), cytokine, growth factor, hormone, drug or prodrug, biologic fluid, plasma protein, plasma glycoprotein or a combination thereof. In some embodiments, HSPCs can be retrieved from the silk scaffold.
The methods to expand and differentiate the HSPCs of the invention may be carried out in static and dynamic culture conditions.
In some embodiments, the 3D silk scaffolds can be cultured into a perfusion chamber. In some embodiments, the flow-through contains cytokines, growth factors, cell-derived secretome, hormones, drugs or prodrugs, biologic fluids,
plasma proteins, plasma glycoproteins or a combination thereof to support differently HSPC expansion and/or differentiation. In some embodiments, the flow rate can be modified to control the distribution of oxygen and nutrients, and shear stress inside the chamber.
In some embodiments, perfusion is performed at shear stresses of 0.05-50 dyn/cm2.
In some embodiments, the perfusion can be continuous, or intermittent (run and stop). In some embodiments, the dynamic culture can be live-imaged during the perfusion.
HSPC expansion
CD34+ HSPCs were obtained from human cord blood or human peripheral blood (purity >90%), and seeded at the concentration of 0.5-5xl03 cells/mm3 in serum-free medium supplemented with 1% penicillin/streptomycin (P/S), 1% L-glutamine, 1 pM SR-1, SCF 100 ng/ml, Flt3-L 100 ng/ml, TPO 10 ng/ml. HSPCs were cultured in a 5% CO2 for at least 14 days in a humidified atmosphere at 37°C.
Megakaryocyte differentiation and platelet production
CD34+ HSPCs were obtained from adult peripheral blood or cord blood. 2- 5xl03 cells/mm3 were seeded into the silk scaffolds. Samples were differentiated for 14 days in serum-free medium supplemented with 1% P/S, 1% L-glutamine, 10 ng/mL TPO, 10 ng/mL IL-11, at 37°C in a 5% CO2 fully humidified atmosphere.
Erythrocyte differentiation and red blood cell production
CD34+ HSPCs were obtained from adult peripheral blood. 2-5xl03 cells/mm3 were seeded into the silk scaffolds. Samples were differentiated for at least 14- 21 days in serum-free medium supplemented with 1% P/S, 1% L-glutamine, 20 ng/mL EPO, 10 ng/mL IL-3, 800 ng - 800 pg/mL holo-transferrin, at 37°C in a 5% CO2 fully humidified atmosphere.
Mature blood cell culture
Mature megakaryocytes, erythrocyte, macrophages or leukocytes were seeded into the silk scaffolds and cultured, at 37 °C in a 5% CO2 fully humidified
atmosphere.
Bone marrow cell culture
Human bone marrow mesenchymal stem cells (MSCs) were cultured in high glucose medium supplemented with sodium pyruvate, 10% MesenCult™ MSC Stimulatory Supplement (Human), 1% L-glutamine, 1% P/S, and 1% non- essential amino acids. MSCs were seeded at a density of l-2xl03 cells/mm3. MSCs were cultured for at least 7 days, before starting the co-cultures.
Osteoblasts were differentiated from human bone marrow MSCs in high glucose medium supplemented with sodium pyruvate, 10% fetal bovine serum (FBS), 1% L-glutamine, 1% P/S, 1% non-essential amino acids, 100 nM dexamethasone, 10 mM sodium P-glycerol phosphate and 50 pM ascorbic acid. The MSCs were left to differentiate into osteoblasts for at least 3 weeks, before starting the co-cultures.
Adipocytes were differentiated from human bone marrow MSCs in high glucose medium supplemented with sodium pyruvate, 1% L-glutamine, 1% P/S, 10% FBS, 0.5 mM isobutyl-methylxanthine, 1 pM dexamethasone, 10 pM insulin, 100 pM indomethacin for three days and maintained in medium with 10% FBS and 10 pM insulin for one day. The treatment was repeated three times, after which the cells were maintained in high glucose medium supplemented with 10% FBS and 10 pM insulin until day 21.
Human umbilical vein endothelial cells (HUVEC), were cultured in medium supplemented with 5% fetal bovine serum, 1% P/S, hEGF, hydrocortisone, GA- 1000, BBE, ascorbic acid. HUVEC were seeded at a density of 1- 2xl03/mm3 and cultured for at least 7 days, before starting the co-cultures.
In some embodiments, the present invention provides methods for highly customizable models of the human bone marrow characterized by their ability to produce differentiated blood cells ex-vivo from HSPCs of healthy subjects or donors with hematological diseases (e.g., genetic diseases, hematologic cancers, etc.). HSPCs can be from cord blood or peripheral blood or bone marrow and can be genetically modified either before or during the 3D culture. It has been observed that, i.e. the production of platelets by using the 3D silk
fibroin scaffolds of the invention in the monolayer or multiplayer format (hydrogel silk scaffold alone or solid-solid silk scaffold in the outer and inner layer of a multilayer silk scaffold of the invention) is at numbers at least an order of magnitude above that achieved by known methods/scaffolds.
The methods to expand and differentiate HSPCs by the silk scaffold of the invention may foresee an additional step of retrieval of the cells from the scaffolds, keeping them vital and functional for clinical applications.
In some embodiments, cells that differentiate within the silk scaffold (e.g., mature platelets, mature enucleated erythrocytes) can be retrieved from the system by perfusion into flow chambers at programmable shear stress.
In a preferred embodiment, the formulation of the solution for the retrieval of the whole cell population from the scaffold of the invention consists of sodium citrate, collagenase, proteinase K, liberase and/or alginate lyase, with a source of glucose, comprises:
- sodium citrate 15 mM
- collagenase 10 U/mL
- alginate lyase 5 U/mL (valid for silk hydrogel only)
- glucose 5 mM
- saline buffer solution up to 100%
The treatment is performed preferably at 37°C for 10-20 minutes.
The present invention further relates to the use of cells released from the scaffold for carrying out morphological, functional, biochemical, and/or molecular analyses which can comprise, by way of example, one or more of the following methods:
- collection of proteins for proteomics, immunoassays, electrophoresis and/or Western blotting assays;
- collection of nucleic acids for genomic characterization, evaluation of the cell karyotype, gene expression analysis via polymerase chain reaction, transcriptomic analyses and/or gene sequencing in all of their variants;
- immune characterization of the released cells;
- imaging;
- enzymatic or colorimetric assays;
- flow cytometric analysis and/or selection of specific cell populations;
- use of cells for functional assays.
It is another object of the present invention a method for the production of a 3D silk fibroin multilayer scaffold comprising the following steps: i) obtaining the porous solid silk scaffold by salt leaching processing or by lyophilizing degummed silk; ii) dispersion of the stem cells of the hematopoietic lineage or progenitor cells into the solid silk scaffold, or into the different layers of solid silk scaffolds, by manual pipetting; iii) mixing the cells within the silk-based hydrogel before dispensing the solution around, or inside, the solid silk scaffold.
According to a preferred embodiment, the inner core is a porous solid silk scaffold obtained by salt leaching processing of 50/60-minute degummed silk (6-8%) or by lyophilizing 30/60-minute degummed silk (2-6%).
A second layer made of a solid silk scaffold ii) is fabricated with salt leaching methods using 10/30-minute degummed silk fibroin.
Alternatively, the first silk scaffold is covered by a silk hydrogel according to the composition mentioned above. The silk hydrogel solution is dispensed at 37°C around the first solid silk scaffold, and then crosslinked at room temperature. According to a preferred embodiment, silk fibroin hydrogel is dispensed by manual pipetting. Alternatively, the hydrogel can be bio-printed around the solid silk fibroin scaffold through an extrusion-based approach with a nozzle having a caliber ranging from 18G to 27G, extrusion pressure within the range of 5-200 kPa, and printing rate within the range of 5-1,000 mm/min. Alternatively, the inner core can be the silk hydrogel according to the composition mentioned above with a solid silk scaffold as the second layer.
The method can further comprise a step iv) of forming a coating of silk around the scaffolds, after cell seeding. The coating layer can form a continuous thin silk structure enclosing the scaffold to control oxygen distribution.
The coating layer around the scaffolds can be formed using 0,5-30% w/v silk
solution by any methods known to a skilled artisan, for example, without limitation, dipping, spraying, electrospinning, gel-spinning, or any combinations thereof.
In a preferred embodiment, the coating is formed by dipping the scaffolds into a 1-10% w/v silk solution, followed by rapid soaking into dehydrating alcohol (e.g., methanol) and/or water-annealing.
According to a preferred embodiment of the invention, the silk scaffold is sterile. The sterility can be advantageously achieved by means of UV-ray sterilization.
The above stem cells of the hematopoietic lineage are preferably mammalian cells, preferably of human origin. HSPCs or differentiated cells of the hematopoietic lineage can derive directly from human blood, preferably HSPCs are multipotent or pluripotent stem cells. More specifically, they can be hematopoietic stem cells (totipotent or pluripotent, including induced pluripotent stem cells and embryonic stem cells), progenitor cells (such as, for example, progenitors of the myeloid or lymphoid lineage, erythrocytes, megakaryocytes), or differentiated blood cells. The differentiated cells of the myeloid lineage derive from a myeloid progenitor and are selected from the group that comprises monocytes, macrophages, granulocytes, neutrophils, basophils, eosinophils, red blood cells, megakaryocytes, platelets, dendritic cells. The differentiated cells of the lymphoid lineage are T lymphocytes, B lymphocytes and NK cells.
According to a particular embodiment of the invention, the cells are human CD34+ HSPCs from cord blood, or peripheral blood, or bone marrow, or human induced pluripotent stem cells, or embryonic stem cells. The cells of the hematopoietic lineage and the other co-cultured cells (e.g., mesenchymal stem cells, osteoblasts, osteoclasts, osteocytes, fibroblasts, endothelial cells, endothelial progenitor cells, perivascular cells, adipocytes, neural stem cells, neurons, leukocytes, granulocytes, monocytes, lymphocytes, neutrophils, eosinophils, basophils, macrophages, erythrocytes, megakaryocytes, platelets, induced pluripotent stem cells and embryonic stem cells) can carry disease-
related genetic mutations or be genetically modified (e.g., plasmid transfection, lentivirus 30 treatment, CRISP/Cas9 system). Genetic modification can be introduced either before or during the 3D culture. The cells of the hematopoietic lineage and the other co-cultured cells can be immortalized (e.g., hematopoietic cell lines, cancer cell lines).
According to a further embodiment of the present invention, the cells of the hematopoietic lineage, including HSPCs and mature blood cells, can be stained with fluorescent antibodies, conjugated or unconjugated, for the visualization of membrane antigens and/or line-specific receptors (e.g., anti-CD3, anti-CD4, anti-CD8, anti-CD34, anti-CD41, anti-CD42a, anti-CD42b, anti-CD45, anti- CD61, anti-CD117, anti-CD235, anti-cMpl) molecular markers (e.g., GFP, TOMATO), fluorescent cytoplasmic tracers (e.g., calcein, carboxyfluorescein succinimidyl ester (CFSE), CellTrac Far Red, CellTracker Deep Red), membrane tracers (e.g. biotinylated or fluorescent lipids and/or phospholipids, 4,4-Difluoro-l,3,5,7,8-Pentamethyl-4-Bora-30, 4°-Diaza-s-Indacene, Annexin
V, fluorescent cholesterol markers), organelles (e.g. fluorescent tracers of mitochondria, endoplasmic reticulum, lysosomes, Golgi apparatus, granules) and/or nucleus (e.g. propidium iodide, 4',6-diamidino-2-phenylindole, Hoechst), tracers of intracellular calcium movements (e.g. Fura-2 AM, Fluo-3
AM, Fluo-4 AM, Rhod-2 AM, Calcium GreenTM-AM). Cells can be stained before or after seeding.
For dynamic culture experiments, the inventors tested the usage of a device manufactured using 3D Low Force Stereolithography (LFS) printing technology. The model was created using software for computer-aided design and slicing. The printing was done using long-term non-toxic biocompatible resins. The flow chamber presented multiple units, each housing one single silk scaffold or a multi-layer scaffold, served by inlet and outlet ports for being connected to a perfusion pump system. The final device was optically clear. Optionally, a glass window could be placed at the bottom, or at the top, of the chamber, ideal for live-cell imaging and high-resolution microscopy using long working distance objectives (e.g., confocal microscopy, multiphoton
microscopy).
Each unit of the chamber was served by independent peristaltic pumps to drive the perfusion of the cell culture medium from a reservoir to the device. At the outlet, a transfusion bag collected the flow-through. In some embodiments, multiple units can be connected in series and perfused by a single common flow-through. The present invention will now be described for illustrative but nonlimiting purposes, according to a preferred embodiment with particular reference to the attached figures, in which:
- Figure 1 illustrates exemplary images of the single and multi-layer scaffolds of the invention (scale bars = 5 mm). The arrow in Panel D indicates the thin silk film surrounding the hydrogel.
- Figure 2 illustrates 3D HSPC culture into silk scaffolds. Panel A shows the confocal imaging of HSPCs co-cultured with mesenchymal stem cells (MSC) into a solid silk scaffold obtained by salt leaching methods (scale bar = 50 pm). Panel B shows the confocal imaging of cells cultured into a solid silk scaffold obtained by lyophilization (scale bar = 50 pm). The analysis of the scaffold after the washout of the cells demonstrated effective retrieval of the whole cell population from 3D culture. Panel C shows the representative analysis of colony-forming units from HSPCs retrieved after 3 days of culture into the different silk scaffolds. Comparable results have been obtained from HSPCs retrieved after 1, 3, or 7 days of 3D culture.
- Figure 3 illustrates HSPCs differentiation into erythrocytes. Panel A shows the confocal microscopy reconstruction of the 3D culture performed into a solid silk scaffold obtained by salt leaching methods (scale bar = 50 pm). Panel A iii highlights the migration of CD68+ macrophages towards maturing erythrocytes. Panel B shows the flow cytometry analysis of cells retrieved after dynamic perfusion of the system. The analysis demonstrated that CD235hlgh cells are released into the flow through.
- Figure 4 illustrates HSPCs differentiation into megakaryocytes. Panel A i shows the confocal microscopy reconstruction of the 3D culture performed into the second layer of a solid silk scaffold obtained by salt leaching methods and cultured with mesenchymal stem cells (scale bar = 50 pm). Panel A ii shows the confocal
microscopy reconstruction of the 3D co-culture mesenchymal stem cells and HSPC in a megakaryocytic differentiation medium. The staining highlights the maturation of CD61+ megakaryocytes forming platelets (scale bar = 20 pm). Panel B shows the confocal microscopy reconstruction of the culture performed in a solid silk scaffold obtained by salt leaching methods and co-cultured with endothelial cells. The staining highlights the maturation of CD61+ megakaryocytes interacting with the endothelium (scale bar = 20 pm). Panel C shows the flow cytometry analysis of the numbers of platelets recovered after the dynamic perfusion of the scaffolds. The number of platelets has been estimated by using counting beads.
- Figure 5 illustrates mature hematopoietic cells into the silk scaffolds. Panel A shows the confocal microscopy reconstruction of the 3D culture of macrophages performed into a solid silk scaffold obtained by salt leaching methods. Panel B shows the confocal microscopy reconstruction of the 3D culture of leukocytes performed into a solid silk scaffold obtained by lyophilization methods.
- Figure 6, Panel i shows the result of the activation of a colorimetric reaction developed in the HRP functionalized scaffolds incubated with 2-16 mM lactate in the presence of lactate oxidase. Lactate-free incubation was used as a negative control. Panel ii shows the colorimetric reaction activated by the lactate released by the same cells grown inside the 3D scaffold. Panel iii shows the comparison between a scaffold cultured with HSPCs and a scaffold cultured in parallel in the absence of HSPCs, as a negative control.
- Figure 7, panel A shows images of the dissolution process of the silk hydrogel obtained with the formulation according to the invention. Dissolution was carried out after 1, 2, 3, 5, and 7 days of culture. The sternness of released HSPCs was confirmed by colony-formation assays. Panel B shows the flow cytometry analysis of CD34+ cells retrieved from the silk hydrogel after 3 days of culture into the scaffold. Panel C shows the colony-forming units formed by HSPCs retrieved from the silk hydrogel after 3 days of culture into the scaffold.
The following non-limiting examples are now provided for a better illustration of the invention, in which different silk fibroin-based scaffolds were tested and compared.
EXAMPLES
Example 1: Silk scaffold preparation
Silk fibroin aqueous solution was obtained from Bombyx mori silkworm cocoons. To prepare pure silk fibroin solution, silkworm cocoons undergo a degumming procedure to separate the silk fibroin fibers from the sericin glue. The molecular weight distribution of silk fibroin chains varies depending on the extraction and purification process utilized to prepare the protein polymer (Sahoo et al., 2020), [10]). Increased degumming time progressively degrades the silk chains resulting in a decrease in the molecular weight from >200 kDa to <90 kDa (experimentally confirmed by Asymmetric Flow Field-Flow Fractionation). Here, dewormed cocoons were boiled for degumming for 10, 20, 30, 40, 50, or 60 minutes in 0.02 M Na2COa solution at a weight to volume ratio of 5 g to 2 L. The fibers were rinsed for 20 min for three times in ultrapure water and dried overnight. The dried fibers were solubilized for 4h at 60°C in LiBr (>9.3 M) at a weight-to-volume ratio of 3 g-12 mL. The solubilized silk solution was dialyzed against distilled water using a Slide-A-Lyzer cassette with a 3500 MW cut-off for three days and changing the water a total of eight times. The silk solution was centrifuged at maximum speed for 10 min to remove large particulates and stored at 4°C. The concentration of the silk solution was determined by drying a known volume of the solution and massing the remaining solids.
1. Solid silk scaffolds
NaCh particles (approximately >300 pm in diameter) were sifted into a silk solution (8% w/v) in a ratio of 1 mL silk/2 g salt, within a molding system (e.g., petri dish, silicon chamber). The scaffolds were then placed at room temperature for 48 hours and then soaked in distilled water for 48 hours to leach out the salt particles. The scaffolds were sterilized in 70% ethanol and finally rinsed five times in PBS over 24 hours.
Alternatively, the silk solution (2% w/v) was cast within a molding system and incubated at -80°C for one day. The frozen solution was then lyophilized for 48-72 hours at -56°C. The lyophilized scaffolds were subsequently autoclaved for 20 minutes to induce the P-sheet formation and stabilize the silk matrix.
2. Hydrogel silk scaffold
Silk hydrogels were composed of:
- silk fibroin 8% w/v
- gelatin or derivatives thereof 15% w/v
- alginic acid or derivatives thereof 1% w/v
- glucose or analogues thereof 3.5% w/v
- Percoll® 2.5% w/v
- HEPES 5% w/v
- albumin 0.1% w/v
- saline buffer solution up to 100% wherein the gelatin and alginic acid are present in a reciprocal ratio of about 15: 1.
The temperature of the silk hydrogel formulation is 37°C when the cells are to be added.
Silk hydrogels were produced at 37°C. After deposition, the silk hydrogel could be crosslinked with a CaCh solution for a minimum of 10 minutes.
The crosslinking solution contains 0.05M CaCh dissolved in a buffer solution containing 150 mM NaCl, 6 mM KC1, 1 mM MgCh, 5 mM glucose, 10 mM HEPES.
3. Multi-layer scaffold fabrication
Solid and hydrogel silk scaffolds could be assembled into 3D multi-layer tissues that mimic the structure and composition of the different bone marrow microenvironments .
The inner core is a porous solid silk scaffold obtained by salt leaching processing of 50 minutes degummed silk (8%) (Figure 1A) or by lyophilizing 30 minutes degummed silk (2%) (Figure IB).
The second layer of the tissue model can be fabricated with salt leaching methods using 30 minutes degummed silk fibroin (Figure 1A) or 50 minutes degummed silk fibroin (Figure IB). A third layer of the tissue model can be fabricated with salt leaching methods using 10 minutes degummed silk fibroin (Figure IB).
The silk hydrogel solution is dispensed at 37°C around the first solid silk scaffold,
and then crosslinked at room temperature (Figure 1C). Silk fibroin hydrogel was dispensed by manual pipetting.
The hydrogel can also be bio-printed around the solid silk fibroin scaffold through an extrusion-based approach with a nozzle having a caliber of 20G, extrusion pressure of 12 kPa, and printing rate of of 500 mm/min.
A silk film can be layers outside the silk hydrogel (Figure ID). The silk film is formed by deeping the multi-layer scaffold into a 2% solution of 30 minutes degummed silk. The system is then soaked into methanol for 2 seconds to allow rapid P-sheet formation and consequent solidification.
Example 2: HSPC expansion and retrieval
To test the ability of the silk scaffolds to support HSPC survival and sternness, human CD34+ were cultured inside 30-minute degummed silk scaffolds obtained either by salt leaching (8% silk solution) (Figure 2A) or lyophilization (2% silk solution) (Figure 2B), either in static condition or under perfusion with the culture medium for up to 4 weeks with a peristaltic pump:
Salt-leaching: rectangular shape, 200 mm3
Lyophilized: cylindrical shape, 400 mm3
In some experiments, HSCPs have been co-cultured with human mesenchymal stem cells (Figure 2A). Mesenchymal stem cells were positioned either in the same scaffold of HSPCs or inside the second layer. The 3D culture was monitored and digitally reconstructed by confocal imaging equipped with a temperature-controlled incubator in a humidified atmosphere and 5% CO2. At the end of the culture, more than 95% of the cells survived in all tested conditions.
HSPC proliferation was analyzed by measuring the number of cells/mm3 by confocal 3D reconstruction. The sternness was determined via colony forming unit (CFU) assays. Cells were retrieved from the silk scaffolds by manual pipetting on days 1, 3, and 7 of 3D culture. The lyophilized silk scaffold allowed a more efficient recovery, with nearly >90% of the cells being pipetted out of the 3D matrix (Figure 2B). Cells were then plated in a methylcellulose-based medium supplemented with penicillin and streptomycin. Two weeks after plating, colonies were identified according to standard morphological criteria and counted in a blinded fashion
(Figure 2C). A significantly increased number of colonies were generated in methylcellulose assays from the 3D cultures with respect to 2D liquid cultures, performed in parallel. Particularly, the number of BFU-E and CFU-GEMM colonies was significantly higher thus demonstrating retained sternness and differentiation capability.
Differentiation assays were performed in situ. HSPCs were cultured for 7 days in a stem cell medium and then differentiated into erythrocytes or megakaryocytes by switching the culture medium, according to the above-described methods. The imaging of the 3D culture demonstrated efficient cell differentiation into enucleated erythrocytes or platelets, respectively. For static cell cultures, the medium was changed every two days to ensure enough moisture in the system. For dynamic cell cultures, the medium was pumped continuously into the system over the course of the culture, for up to 4 weeks, changing the medium reservoir based on the experimental conditions.
HSPCs co-culture with osteoblasts, seeded into the second layer of the scaffold, demonstrated retained cell proliferation and stem cell profile, even in a medium containing differentiating cytokines (e.g., thrombopoietin). On the opposite, in the presence of mesenchymal stem cells and a megakaryocytic differentiating medium, we observed the proliferation of fully mature megakaryocytes forming increased numbers of platelets with respect to standard liquid cultures.
Example 3.~ Erythroid differentiation and red blood cell enucleation
HSPCs were seeded into a 30-minute degummed silk scaffold obtained by salt leaching (8% silk solution) and functionalized with fibronectin. The scaffold was filled with enough medium to keep it constantly wet. Cell differentiation was analyzed by means of different microscopy and flow cytometry approaches. We investigated the spatial distribution of cells within the sponge and observed a tendency of developing cellular nests typically resembling the physiological organization of bone marrow erythroblastic island (Figure 3A i, ii). To investigate the influence of 3D spatial distribution on erythrocyte maturation, we evaluated the expression of lineage- specific surface markers and compared it to 2D cultures. The differentiation patterns were similar in the early-intermediate phases of
erythropoiesis, as demonstrated by a comparable percentage of CD235+CD71+ cells. A striking difference could be observed in the terminal phase of maturation. Indeed, the amount of CD235+CD71‘ cells was substantially higher than the 3D cultured cells, suggesting that our silk scaffold effectively supported enucleation. Of note, enucleated CD235+CD71‘ cells were mainly localized at the periphery of the cellular aggregate or next to co-cultured CD68+ macrophage (Figure 3A iii). After two weeks of static culture, the scaffold has been dynamically perfused to assess the effect of laminar flow on erythrocyte terminal differentiation, particularly during the enucleation phase. The flow-through has been collected into a transfusion bag. Flow cytometry analysis demonstrated the recovery of enucleated CD235+CD71‘ cells only while maturing erythroblasts were retained within the scaffold (Figure 3B). The recovered cell population demonstrated also a significantly decreased expression of alpha4betal integrin, which was retained only by immature erythroblasts to favor their adhesion to fibronectin-functionalized silk scaffolds.
Example 4: Megakaryocyte differentiation and platelet production
Bone marrow cell behavior is regulated by cell-intrinsic and cell-extrinsic forces. Mechanical forces determine mesenchymal stem cells fate (e.g., differentiation into the osteoblast or adipocyte-committed lineage) as well as remodeling of the ECM components. We can regulate mesenchymal stem cell behavior in the niche by changing the mechanical properties of the silk. The scaffolds obtained from the shortest degumming time (10 minutes) exhibited the highest rigidity vs 30- and 50- minute degumming time, as demonstrated by atomic force microscopy-based nanoindentation.
By exploiting these parameters, we fabricated diverse silk tissue models for creating discrete microenvironments able to mimic the different niches that are present in the bone marrow in vivo. The first consisted of a scaffold obtained by the salt leaching approach using 10-minute degummed silk fibroin. The resulting structure confers high mechanical performance and resistance to promote osteogenic induction to human bone marrow mesenchymal stem cells. After two weeks of culture, cells showed an osteoblastic profile as demonstrated by increased
nucleation of calcium phosphate, expression of alkaline phosphatase, and deposition of type I collagen. The second scaffold was obtained using 30-minute degummed silk fibroin. This softer model supported mesenchymal stem cell growth and deposition of ECM components.
Co-culturing HSPCs into silk scaffolds containing either mesenchymal stem cells (Figure 4A), endothelial cells (Figure 4B), or endothelial-cell derived recombinant proteins (e.g., VEGF, VCAM1, SDF-lalpha), in the presence of a megakaryocytic differentiating medium prolonged megakaryocyte survival and greatly enhanced platelet production in dynamic perfusion. Multi-layer scaffolds were inserted into the 3D printed flow chamber, connected to a syringe pump at the inlet and to a gas- permeable collection bag, containing anticoagulant, at the outlet, and placed into an incubator at 37°C and 5% CO2.
The porous silk structure of the scaffolds ensured immediate binding at the interface of the two layers that remained discrete but interconnected entities. Samples have been fed continuously with the culture medium to ensure oxygenation and transport of nutrients through the scaffold. The flow-through is distributed homogeneously within all the layers. Platelet count at the outlet was assessed by flow cytometry by mixing samples with counting beads. Platelets were identified based on the expression of CD41 and CD42b surface markers. The comparison of platelet counts among the different test conditions demonstrated a significant increase in the yield of platelets from megakaryocytes into multi-layers silk scaffold containing mesenchymal stem cells (Figure 4C) or endothelial cells, with respect to megakaryocytes alone (*p<0.05).
Example 5: Culture of mature blood cells
Erythrocytes, megakaryocytes, macrophages, or leukocytes were seeded into a 30- minute degummed silk scaffold obtained by salt leaching (8% silk solution) or by lyophilization (2% silk solution) and functionalized with fibronectin. The scaffold was filled with enough medium to keep it constantly wet. Cells were imaged by means of confocal microscopy (Figure 5).
Example 6: Bioactive silk scaffolds: dosage of lactate released by the cells during culture
In order to demonstrate the bioactivity of the silk scaffolds, we functionalized the silk solution with 110 U/mL of horseradish peroxidase (HRP) enzyme before producing the solid silk scaffold or hydrogel, using the same methods described above. The bioactivity was evaluated after several days of culture by activating a reaction leading to chemiluminescence in the presence of luminol and hydrogen peroxide. The chemiluminescent signal was acquired using a chemiluminescence detector. In all the conditions tested, the enzymatic activity was detectable. The functionalized scaffolds were also tested in the presence of hematopoietic progenitors for dosing molecules released during the 3D culture by the cells themselves, without the need for manipulating the scaffold. In particular, the release of lactate, a product of glycolysis, indicative of an active cellular metabolism and whose variation can be indicative of alterations in HSPC proliferation and/or differentiation, was analyzed. For this purpose, a solution of 20 U/mL of lactate oxidase, 600 ng/mL of sodium 3,5-dichloro-2-hydroxybenzenesulfonate (DHBS), and 100 ng/mL of 4-aminoantipyrine (4-AAP) was dispensed onto the scaffolds. Alternatively, the reagents can be added directly to the silk solution before producing the scaffolds. In both cases, the bioactivity of the preparation was confirmed by the activation of a colorimetric reaction following incubation with lactate (2-16 mM) (Figure 6 i). Lactate-free incubation was used as a negative control. The presence of increasing concentrations of lactate released by the cells was detected during the culture of the bioprinted 3D scaffold (Figure 6 ii, iii). The specificity of the reaction was confirmed by treating the sample with the lactate dehydrogenase inhibitor.
Example 7 : Dissolution of the silk hydrogel
In order to test the possibility of recovering the cells from the silk hydrogel after 3D culture, and using them for functional, biochemical or molecular studies, HSPCs were cultured for 7 days in a stem medium and then incubated in the dissolution solution (according to the invention), at 37°C for 20 minutes (Figure 7A).
The cells were then centrifuged at 1,200 rpm for 10 minutes, washed in a physiological solution, and used in the experimental assays.
The morphological parameters and the expression of surface antigens of the stem
cell lineage were evaluated by immunofluorescence microscopy and flow cytometry after incubation with specific antibodies (Figure 7B). Cells were then plated in a methylcellulose-based medium supplemented with penicillin and streptomycin. Two weeks after plating, colonies were identified according to standard morphological criteria and counted in a blinded fashion. The colonyformation assay demonstrated retained sternness and differentiation capability of cells retrieved from the 3D cultures (Figure 7C).
REFERENCES
[1] Di Buduo CA, Aguilar A, Soprano PM, Bocconi A, Miguel CP, Mantica G, Balduini A. Latest culture techniques: cracking the secrets of bone marrow to mass-produce erythrocytes and platelets ex vivo. Haematologica. 2021 Apr l;106(4):947-957. doi: 10.3324/haematol.2020.262485. PMID: 33472355
[2] Khan AO, Colombo M, Reyat JS, Wang G, Rodriguez-Romera A, Wen WX, Murphy L, Grygielska B, Mahoney C, Stone A, Croft A, Bassett D, Poologasundarampillai G, Roy A, Gooding S, Rayes J, Machlus KR, Psaila B. Human bone marrow organoids for disease modelling, discovery and validation of therapeutic targets in hematological malignancies. bioRxiv 2022.03.14.483815; doi: https://doi.org/10.1101/2022.03.14.483815
[3] Pallotta I, Lovett M, Kaplan DL, Balduini A. Three-dimensional system for the in vitro study of megakaryocytes and functional platelet production using silk-based vascular tubes. Tissue Eng Part C Methods. 2011 Dec;17(12): 1223-32. doi: 10.1089/ten.tec.2011.0134. Epub 2011 Sep 6. PMID: 21895494
[4] Di Buduo CA, Wray LS, Tozzi L, Malara A, Chen Y, Ghezzi CE, Smoot D, Sfara C, Antonelli A, Spedden E, Bruni G, Staii C, De Marco L, Magnani M, Kaplan DL, Balduini A. Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies. Blood. 2015 Apr 2;125(14):2254-64. doi: 10.1182/blood-2014-08-595561. Epub 2015 Jan 9. PMID: 25575540
[5] Di Buduo CA, Wray L, Tozzi L, Chen Y, Kaplan DL, Balduini A.
WO2016/022834 Al. Microphysiologic methods and compositions.
[6] Di Buduo CA, Soprano PM, Tozzi L, Marconi S, Auricchio F, Kaplan DL, Balduini A. Modular flow chamber for engineering bone marrow architecture and function. Biomaterials. 2017 Nov; 146:60-71. doi: 10.1016/j. biomaterials.2017.08.006. Epub 2017 Aug 8. PMID: 28898758
[7] Tozzi L, Laurent PA, Di Buduo CA, Mu X, Massaro A, Bretherton R, Stoppel W, Kaplan DL, Balduini A. Multi-channel silk sponge mimicking bone marrow vascular niche for platelet production. Biomaterials. 2018 Sep;178:122-133. doi: 10.1016/j. biomaterials.2018.06.018. Epub 2018 Jun 17. PMID: 29920404
[8] Di Buduo CA, Laurent PA, Zaninetti C, Lordier L, Soprano PM, Ntai A, Barozzi S, La Spada A, Biunno I, Raslova H, Bussel JB, Kaplan DL, Balduini CL, Pecci A, Balduini A. Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients. Elife. 2021 Jun l;10:e58775. doi: 10.7554/eLife.58775. PMID: 34059198
[9] Di Buduo CA, Kalpan DL, Balduini A. Systems and methods for assessing patient-specific response to thrombopoietin-receptor agonists. W02021/113830 AL
[10] Sahoo JK, Choi J, Hasturk O, Laubach I, Descoteaux ML, Mosurkal S, Wang B, Zhang N, Kaplan DL. Silk degumming time controls horseradish peroxidase-catalyzed hydrogel properties. Biomater Sci. 2020 Jul 28;8(15):4176-4185. doi: 10.1039/d0bm00512f. PMID: 32608410
Claims
1. A 3D silk fibroin multi-layer scaffold comprising at least two interconnected silk scaffolds: i) an inner core made of a porous solid silk fibroin scaffold or of a silk fibroin hydrogel comprising stem cells of the hematopoietic lineage; ii) at least one silk fibroin scaffold surrounding the inner scaffold i) made of silk fibroin hydrogel or porous solid silk fibroin scaffold comprising differentiated or undifferentiated cells, selected from hematopoietic stem cells, hematopoietic progenitor cells, mature blood cells, and/or non-hematopoietic cell types.
2. A 3D silk fibroin multi-layer scaffold according to claim 1, wherein the undifferentiated cells of the silk fibroin scaffold ii) are stem and progenitor cells of the hematopoietic lineage, when the 3D silk fibroin multi-layer scaffold further comprises an additional silk layer.
3. A 3D silk fibroin multi-layer scaffold according to anyone of the claims 1-
2, wherein the stem cells of the hematopoietic lineage are HSPCs, induced pluripotent stem cells, or embryonic stem cells.
4. A 3D silk fibroin multi-layer scaffold according to anyone of the claims 1-
3, wherein said hematopoietic stem cells, hematopoietic progenitor cells or mature blood cells are selected from the group comprising leukocytes, granulocytes, monocytes, lymphocytes, neutrophils, eosinophils, basophils, macrophages, erythrocytes, platelets, megakaryocytes, hematopoietic stem cells, induced pluripotent stem cells, or embryonic stem cells, and wherein said non-hematopoietic cell types are selected from the group comprising osteoblasts, osteoclasts, osteocytes, fibroblasts, endothelial cells, perivascular cells, adipocytes, neurons, mesenchymal stem cells, endothelial progenitor cells, neural stem cell, induced pluripotent stem cells, or embryonic stem cells.
5. A 3D silk fibroin multi-layer scaffold according to anyone of the claims 1-
4, wherein the porous solid silk fibroin scaffold comprises interconnected pores having a diameter > 5 pm.
6. A 3D silk fibroin multi-layer scaffold according to anyone of claims 1-5,
wherein said silk fibroin and/or hydrogel scaffold i) or ii), comprises a coculture with a second differentiated or undifferentiated cell population selected from the group consisting of mesenchymal stem cells, osteoblasts, osteoclasts, osteocytes, fibroblasts, endothelial cells, endothelial progenitor cells, perivascular cells, adipocytes, neural stem cells, neurons, leukocytes, granulocytes, monocytes, lymphocytes, neutrophils, eosinophils, basophils, macrophages, erythrocytes, platelets, megakaryocytes, induced pluripotent stem cells, or embryonic stem cells.
7. A 3D silk fibroin multi-layer scaffold according to anyone of claims 1-6, wherein the silk fibroin and/or hydrogel scaffold i) or ii) is functionalized with one or more bioactive molecules selected among the group comprising: components of the extracellular matrix selected from the group consisting of proteoglycans, hyaluronic acid, collagens, elastin, fibronectin, fibrin, fibrinogen, laminins, thrombospondin;
- growth factors, cytokines, and chemokines, interleukins, CSF-1, G-CSF, M- CSF, GM-CSF, SCF, FLT3-L, TPO, EPO, SDF-la; TGF- 1, TNFa, VEGF, FGF, Notch ligands, WNT, angiopoietin-1, BMP, IGF-2, and fragments or variants thereof;
- polyol compounds such as glycerol;
- plasma proteins or glycoproteins, selected among albumin, globulins, transferrin, and immunoglobulins;
- cellular secretome and cell-derived growth factors (e.g., platelet secretome, leukocyte secretome, platelet-derived growth factors);
- lipids, cholesterol, and lipoproteins;
- biologic fluids such as whole blood, bone marrow aspirate, blood serum or plasma, bone marrow serum or plasma, or cell-culture supernatants;
- cell-derived interacting motifs, antigens, conjugated or unconjugated antibodies, or their fragments such as CDRs or epitopes;
- hormones, such as insulin, glucagon, triiodothyronine, thyroxine, steroid hormones or their antagonists;
- drugs or prodrugs, such as TPO mimetics, TPO receptor agonists, tyrosine
kinase receptor agonists, tyrosine kinase receptor inhibitors, Rho kinase inhibitors, kinase inhibitors, receptor antagonists of aryl hydrocarbons, chemotherapeutic agents, monoclonal antibodies, polyclonal antibodies;
- nucleic acids, such as DNA, RNA, siRNA, RNAi and microRNA, plasmids, lentiviruses, CRISPRs;
- enzymes, such as horseradish peroxidase, and/or their substrates or intermediates of enzymatic reactions.
- toxins.
8. A 3D silk fibroin multi-layer scaffold according to anyone of claims 1-7, further comprising a thin coating layer of silk fibroin surrounding the outer scaffold to control oxygen distribution.
9. A 3D silk fibroin multi-layer scaffold according to anyone of claims 1-8, wherein the porous solid silk scaffold is obtained by salt leaching processing or by lyophilizing degummed silk fibroin.
10. A 3D silk fibroin multi-layer scaffold according to anyone of the preceding claims, wherein the silk fibroin hydrogel is dispensed around the inner scaffold by pipetting or bio-printing.
11. A 3D silk fibroin multi-layer scaffold according to anyone of the preceding claims wherein the thin coating layer of silk fibroin surrounding the outer scaffold is formed by dipping, spraying, electrospinning, gel-spinning, or a combination thereof.
12. A 3D porous solid silk fibroin scaffold in a monolayer or multilayer format wherein pores have a diameter > 5 pm, obtained by salt leaching processing or by lyophilizing degummed silk fibroin, which is dispersed with stem cells of the hematopoietic lineage alone or in co-culture with differentiated or undifferentiated cells.
13. Use of a 3D silk fibroin monolayer or multilayer scaffold according to anyone of the claims 1-12, as ex-vivo model for keeping sternness, supporting hematopoiesis or for the production of mature blood cells by expansion and differentiation of stem cells of the hematopoietic lineage alone or in co-culture with differentiated or undifferentiated cells, in static or dynamic culture.
14. Use of a 3D silk fibroin monolayer or multilayer scaffold according to anyone of the claims 1-12, as a surgical implant for keeping sternness, supporting hematopoiesis or for the production of mature blood cells in vivo.
15. Use according to claim 13 or 14, wherein said mature blood cells are erythrocytes, megakaryocytes or platelets.
16. Method for expansion and/or differentiation of stem cells of the hematopoietic lineage, wherein the 3D silk fibroin monolayer or multilayer scaffold according to anyone of claim 1-12, is cultured in static conditions of perfused into dynamic flow chambers with a cell culture medium comprising at least one nutrient, cytokine, growth factor, hormone, antibody, drug or a combination thereof.
17. Method for the production of a 3D silk fibroin multilayer scaffold comprising the following step: i) obtaining the porous solid silk scaffold by salt leaching processing or by lyophilizing degummed silk; ii) dispersion of the stem cells of the hematopoietic lineage or progenitor cells into the solid silk scaffolds by manual pipetting; iii) mixing the co-cultured differentiated cells within the silk-based hydrogel before dispensing the solution around the solid silk scaffold.
18. Method according to claim 17, comprising a further step iv) of forming a silk coating around the scaffolds by dipping, spraying, electrospinning, gel-spinning, or a combination thereof.
19. Method according to anyone of the claims 17-18, further comprising a retrieval step of the cell population from the scaffolds using a solution consisting of sodium citrate, collagenase, proteinase K, liberase and/or alginate lyase, with a source of glucose.
20. Method according to anyone of the claims 16-19, wherein said stem cells of the hematopoietic lineage are HSPCs, induced pluripotent stem cells, or embryonic stem cells.
21. Method according to anyone of the claims 16-20, wherein the differentiated cells are selected from the group comprising mammalian, osteoblasts, osteoclasts, osteocytes, fibroblasts, endothelial cells, perivascular cells,
adipocytes, neurons, leukocytes, monocytes, lymphocytes, neutrophils, eosinophils, basophils, macrophages, erythrocytes, platelets, or megakaryocytes and the undifferentiated cells are selected from the group comprising hematopoietic stem cells, mesenchymal stem cells, endothelial progenitor cells, neural stem cell, induced pluripotent stem cells, or embryonic stem cells.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT202200017079 | 2022-08-10 | ||
IT102022000017079 | 2022-08-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2024033385A1 true WO2024033385A1 (en) | 2024-02-15 |
Family
ID=83506266
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2023/071983 WO2024033385A1 (en) | 2022-08-10 | 2023-08-08 | Methods for hematopoietic stem and progenitor cell expansion and differentiation in three-dimensional silk scaffolds and uses thereof |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2024033385A1 (en) |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016022834A1 (en) | 2014-08-07 | 2016-02-11 | Tufts University | Microphysiologic methods and compositions |
WO2021113830A1 (en) | 2019-12-06 | 2021-06-10 | Trustees Of Tufts College | Systems and methods for assessing patient-specific response to thrombopoietin-receptor agonists |
-
2023
- 2023-08-08 WO PCT/EP2023/071983 patent/WO2024033385A1/en unknown
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2016022834A1 (en) | 2014-08-07 | 2016-02-11 | Tufts University | Microphysiologic methods and compositions |
WO2021113830A1 (en) | 2019-12-06 | 2021-06-10 | Trustees Of Tufts College | Systems and methods for assessing patient-specific response to thrombopoietin-receptor agonists |
Non-Patent Citations (12)
Title |
---|
CHATTERJEE CHANDRALEKHA ET AL: "Rebuilding the hematopoietic stem cell niche: Recent developments and future prospects", ACTA BIOMATERIALIA, ELSEVIER, AMSTERDAM, NL, vol. 132, 1 April 2021 (2021-04-01), pages 129 - 148, XP086767351, ISSN: 1742-7061, [retrieved on 20210401], DOI: 10.1016/J.ACTBIO.2021.03.061 * |
DI BUDUO CAAGUILAR ASOPRANO PMBOCCONI AMIGUEL CPMANTICA GBALDUINI A: "Latest culture techniques: cracking the secrets of bone marrow to mass-produce erythrocytes and platelets ex vivo", HAEMATOLOGICA, vol. 106, no. 4, 1 April 2021 (2021-04-01), pages 947 - 957 |
DI BUDUO CALAURENT PAZANINETTI CLORDIER LSOPRANO PMNTAI ABAROZZI SLA SPADA ABIUNNO IRASLOVA H: "Miniaturized 3D bone marrow tissue model to assess response to Thrombopoietin-receptor agonists in patients", ELIFE, vol. 10, 1 June 2021 (2021-06-01), pages 58775 |
DI BUDUO CASOPRANO PMTOZZI LMARCONI SAURICCHIO FKAPLAN DLBALDUINI A: "Modular flow chamber for engineering bone marrow architecture and function", BIOMATERIALS, vol. 146, 8 August 2017 (2017-08-08), pages 60 - 71 |
DI BUDUO CAWRAY LSTOZZI LMALARA ACHEN YGHEZZI CESMOOT DSFARA CANTONELLI ASPEDDEN E: "Programmable 3D silk bone marrow niche for platelet generation ex vivo and modeling of megakaryopoiesis pathologies", BLOOD, vol. 125, no. 14, 9 January 2015 (2015-01-09), pages 2254 - 64 |
DI BUDUO CHRISTIAN A. ET AL: "Latest culture techniques: cracking the secrets of bone marrow to mass-produce erythrocytes and platelets ex vivo", vol. 106, 21 January 2021 (2021-01-21), IT, XP093029362, ISSN: 0390-6078, Retrieved from the Internet <URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017859/pdf/106947.pdf> DOI: 10.3324/haematol.2020.262485 * |
ISABELLA PALLOTTA ET AL: "Three-Dimensional System for the In Vitro Study of Megakaryocytes and Functional Platelet Production Using Silk-Based Vascular Tubes", TISSUE ENGINEERING PART C: METHODS, vol. 17, no. 12, 1 December 2011 (2011-12-01), pages 1223 - 1232, XP055108904, ISSN: 1937-3384, DOI: 10.1089/ten.tec.2011.0134 * |
KHAN AOCOLOMBO MREYAT JSWANG GRODRIGUEZ-ROMERA AWEN WXMURPHY LGRYGIELSKA BMAHONEY CSTONE A, HUMAN BONE MARROW ORGANOIDS FOR DISEASE MODELLING, DISCOVERY AND VALIDATION OF THERAPEUTIC TARGETS IN HEMATOLOGICAL MALIGNANCIES, Retrieved from the Internet <URL:https://doi.org/10.1101/2022.03.14.483815> |
MAHDAVI MOHAMMAD REZA ET AL: "Electrospun silk nanofibers promoted the in vitro expansion potential of CD 133+ cells derived from umbilical cord blood", GENE, ELSEVIER AMSTERDAM, NL, vol. 809, 18 October 2021 (2021-10-18), XP086877215, ISSN: 0378-1119, [retrieved on 20211018], DOI: 10.1016/J.GENE.2021.146005 * |
PALLOTTA ILOVETT MKAPLAN DLBALDUINI A: "Three-dimensional system for the in vitro study of megakaryocytes and functional platelet production using silk-based vascular tubes", TISSUE ENG PART C METHODS, vol. 17, no. 12, 6 September 2011 (2011-09-06), pages 1223 - 32, XP055108904, DOI: 10.1089/ten.tec.2011.0134 |
SAHOO JKCHOI JHASTURK OLAUBACH IDESCOTEAUX MLMOSURKAL SWANG BZHANG NKAPLAN DL: "Silk degumming time controls horseradish peroxidase-catalyzed hydrogel properties", BIOMATER SCI., vol. 8, no. 15, 28 July 2020 (2020-07-28), pages 4176 - 4185 |
TOZZI LLAURENT PADI BUDUO CAMU XMASSARO ABRETHERTON RSTOPPEL WKAPLAN DLBALDUINI A: "Multi-channel silk sponge mimicking bone marrow vascular niche for platelet production", BIOMATERIALS, vol. 178, 17 June 2018 (2018-06-17), pages 122 - 133 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Sullenbarger et al. | Prolonged continuous in vitro human platelet production using three-dimensional scaffolds | |
Li et al. | Human cord cell hematopoiesis in three-dimensional nonwoven fibrous matrices: in vitro simulation of the marrow microenvironment | |
Raic et al. | Biomimetic macroporous PEG hydrogels as 3D scaffolds for the multiplication of human hematopoietic stem and progenitor cells | |
JP5067949B2 (en) | Method for culturing and subculture of primate embryonic stem cells and method for inducing differentiation thereof | |
US20050265980A1 (en) | Cell culture environments for the serum-free expansion of mesenchymal stem cells | |
US20110207175A1 (en) | Multi-culture bioreactor system | |
AU2002360741B2 (en) | Endothelial stem cells, populations, methods of isolation and use thereof | |
EP2970914B1 (en) | A method of isolating cells for therapy and prophylaxis | |
Huang et al. | Solid freeform-fabricated scaffolds designed to carry multicellular mesenchymal stem cell spheroids for cartilage regeneration | |
JP2015511482A (en) | 3D in vitro biphasic cartilage structure | |
Tavakol et al. | Injectable, scalable 3D tissue-engineered model of marrow hematopoiesis | |
Eicke et al. | Large-scale production of megakaryocytes in microcarrier-supported stirred suspension bioreactors | |
Ingavle et al. | Mimicking megakaryopoiesis in vitro using biomaterials: Recent advances and future opportunities | |
JP2014060991A (en) | Method of culturing stem cells using inner lumen of porous hollow fiber | |
CN115305233A (en) | Preparation and application of daidzein and apigenin composite agarose-collagen hydrogel three-dimensional culture stem cells and extracellular vesicles | |
WO2005100549A1 (en) | Method of proliferating organ-specific stem cell and proliferation apparatus therefor | |
Zhou et al. | Study on a 3D-Bioprinted tissue model of self-assembled nanopeptide hydrogels combined with adipose-derived mesenchymal stem cells | |
CN110951686A (en) | Hematopoietic stem cell in-vitro amplification culture system and method | |
WO2024033385A1 (en) | Methods for hematopoietic stem and progenitor cell expansion and differentiation in three-dimensional silk scaffolds and uses thereof | |
Frese et al. | Are adipose‐derived stem cells cultivated in human platelet lysate suitable for heart valve tissue engineering? | |
WO2021065984A1 (en) | Method for forming sheet of cardiomyocytes | |
Gautrot et al. | Biomimetic Artificial Bone Marrow Niches for the Scale Up of Hematopoietic Stem Cells | |
Way et al. | Cytocentrifugation: a convenient and efficient method for seeding tendon-derived cells into monolayer cultures or 3-D tissue engineering scaffolds | |
Mousavi et al. | Potential of Polycaprolactone Nanofiber Scaffold for Ex Vivo Expansion of Cord Blood-Derived CD34+ Hematopoietic Stem Cells | |
WO2016022834A1 (en) | Microphysiologic methods and compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 23755051 Country of ref document: EP Kind code of ref document: A1 |